A thieno[2,3-d]pyrimidine scaffold is a novel negative allosteric modulator of the dopamine D2 receptor by Fyfe, Tim J. et al.
  
This document is confidential and is proprietary to the American Chemical Society and its authors. Do not 
copy or disclose without written permission. If you have received this item in error, notify the sender and 
delete all copies. 
 
 
 
A Thieno[2,3-d]pyrimidine Scaffold is a Novel Negative 
Allosteric Modulator of the Dopamine D2 Receptor 
 
 
Journal: Journal of Medicinal Chemistry 
Manuscript ID jm-2017-01565m.R2 
Manuscript Type: Article 
Date Submitted by the Author: 16-Apr-2018 
Complete List of Authors: Fyfe, Tim; Monash Institute of Pharmaceutical Sciences, Medicinal 
Chemistry 
Zarzycka, Barbara; University of Southern California 
Lim, Herman; Monash Institute of Pharmaceutical Sciences, Drug Discovery 
Biology 
Kellam, Barrie; University of Nottingham, School of Pharmacy 
Mistry, Shailesh; University of Nottingham, Pharmacy 
Katritch, Vsevolod; University of Southern California, BISC 
Scammells, Peter; Monash University, Medicinal Chemistry 
Lane, J. Robert; Monash Institute of Pharmaceutical Sciences, Drug 
Discovery Biology 
Capuano, Ben; Monash Institute of Pharmaceutical Sciences, Medicinal 
Chemistry 
  
 
 
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1A Thieno[2,3-d]pyrimidine Scaffold is a Novel Negative Allosteric Modulator of
the Dopamine D2 Receptor
Tim J. Fyfe,†,§,∥Barbara Zarzycka,‡ Herman D. Lim,§ Barrie Kellam,∥ Shailesh N. Mistry,∥
Vsevolod Katrich,‡,≠ Peter J. Scammells,† J. Robert Lane,*,§ Ben Capuano*,†
†Medicinal Chemistry, and §Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash
University, Parkville, Victoria 3052, Australia
∥School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7 2RD,
U.K
‡Department of Biological Sciences, Bridge Institute, University of Southern California, Los Angeles, CA
90089, United States.
≠Department of Chemistry, Bridge Institute, University of Southern California, Los Angeles, CA 90089,
United States.
Abstract: Recently, a novel negative allosteric modulator (NAM) of the D2-like dopamine receptors 1 was
identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does
not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric
mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural determinants
of this allostery. We find that key structural moieties are important for functional affinity and negative
cooperativity, whilst functionalization of the thienopyrimidine at the 5- and 6-positions results in analogues
with divergent cooperativity profiles. Successive compound iterations have yielded analogues exhibiting a 10-
fold improvement in functional affinity, as well as enhanced negative cooperativity with dopamine affinity
and efficacy. Furthermore, our study reveals a fragment-like core that maintains low µM affinity and robust
negative cooperativity with markedly improved ligand efficiency.
 INTRODUCTION
The dopamine D2 receptor (D2R), a class A G protein-coupled receptor (GPCR), is a therapeutic target for
central nervous system disorders such as schizophrenia and Parkinson’s disease. Accordingly, it has been the
subject of intensive drug discovery efforts for the last 60 years. Such efforts have focused on targeting the
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2orthosteric binding site of the D2R where dopamine (DA) binds.1, 2 Clinically marketed drugs indicated for the
treatment of schizophrenia display efficacy with respect to treating the positive symptoms of the disease.
These drugs all act either as competitive antagonists or partial agonists at the D2R. However, these drugs can
cause deleterious side-effects. First-generation antipsychotics (FGAs) are associated with a high frequency of
extrapyramidal motor symptoms (EPS) caused by antagonism of D2R signaling in the nigrostriatal system.3
Although, second generation antipsychotic (SGAs) are thought to be associated with a lower risk of EPS such
drugs are associated with other limiting side effects such as metabolic side effects.4
In order to adequately address the unmet medical need associated with antipsychotic drug discovery, novel
approaches are required. NAMs that display limited negative cooperativity with dopamine have been proposed
as a safer therapeutic option to treat the positive symptoms of schizophrenia, in particular for the onset of EPS,
because they would cause only partial blockade of the D2R.5 Indeed, targeting allosteric sites within GPCRs
may be associated with a number of advantages over classical orthosteric drug discovery such as improved
subtype-selectivity and thus reduced off-target side-effects, as well as maintenance of spatiotemporal patterns
associated with endogenous neurohumoral signalling because they still allow the endogenous neurotransmitter
to bind the receptor.6,7
Virtual screening of orthosteric and putative allosteric sites within the human dopamine D3 receptor
(D3R) recently identified an active thienopyrimidine compound (1, Figure 1).8 In this study, screening was
undertaken using two optimised crystal-structure-based models (PDB ID: 3PBL)9: the receptor with an empty
(unliganded) binding pocket (D3RAPO), and the receptor complex with DA (D3RDopa). In particular, D3RDopa
was used to screen for allosteric compounds that can bind along with the endogenous ligand. Interestingly, 1,
although identified using D3RAPO, was predicted to bind in an allosteric pose and showed the highest potency
of DA inhibition in vitro.8 Furthermore, this compound also displayed activity at the D2R, and as such, may
represent a novel allosteric scaffold for this receptor.
To date, very few ligands have been characterised as allosteric modulators of D2-like dopamine receptors
including the drug-like ligand SB269652 (Figure 1); which acts to negatively modulate dopamine affinity at
the D2R and D3R.10-12 Structure-based virtual ligand screening (VLS) provides an attractive path for efficient
discovery of allosteric ligands. However, it is important to validate this approach through optimisation of
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3initial VLS hits.13,14 Currently, there is no structure-activity relationship (SAR) data associated with 1, but
there is much scope for further structural interrogation. We therefore undertook a study to identify novel
allosteric modulators for the D2R, based on the structure of 1. Through modifications to the scaffold of 1, we
aimed to identify key molecular features responsible for its allosteric action at the D2R (Figure 2). We applied
analytical pharmacological methods to allow us to supplement this SAR study with measures of allosteric
ligand action to include not only allosteric ligand affinity (KB), but also the magnitude of modulatory effects
upon dopamine affinity (α) and efficacy (β). Such an approach may be useful as a starting point to understand
the relationship between allosteric ligand behavior and the in vivo efficacy of such modulators. Indeed, to
explore negative allosteric modulation as an approach to treat the positive symptoms of schizophrenia it would
be advantageous to have a set of D2R NAMs that display a range of different allosteric behaviors from
modulation of dopamine affinity through to modulation of dopamine efficacy. Herein, we report the design,
synthesis, and detailed pharmacological characterisation of 1, together with a library of structural analogues.
We provide evidence that 1 does indeed act via an allosteric site at the D2R and reveal that 1 exerts distinct
pharmacology to that of SB269652, whereby it acts to modulate dopamine efficacy rather than dopamine
affinity. Promising low molecular weight candidates with marketedly improved lipophilic ligand efficiencies
(LLE) have been identified, and thus represent an attractive starting point for the development of novel D2R
NAMs that modulate dopamine efficacy, affinity or both.
Figure 1. Compound 1 (above left) (2-(morpholinomethyl)-N-(3-(trifluoromethyl)phenyl)-5,6,7,8-
tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine) (above left) was identified from a virtual ligand
screen targeting orthosteric and allosteric pockets of the dopamine D2-like receptors. SB269652 (2) (above
right), is the first drug-like NAM of the dopamine D2 receptor.10
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4 RESULTS & DISCUSSION
Chemistry. In order to validate the pharmacological activity of lead compound 1, it was resynthesised using
a five step chemical synthesis outlined in Scheme 1.15 Gewald chemistry permitted the one-pot assembly of
ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 5 via commercially available
cyclohexanone 2, ethyl cyanoacetate 3 and sulfur, catalysed by diethylamine in absolute ethanol at 60 °C to
afford the fused thiophene 5 as brilliant orange needles.15 Next, 5 was subjected to an acid catalysed
intermolecular cyclisation in 1,4-dioxane at room temperature using chloroacetonitrile and hydrogen chloride
gas generated in situ (Kipp’s apparatus) to yield the 2-chloro substituted thieno[2,3-d]pyrimidin-4(3H)-one
core scaffold 6 as a precipitated white solid.16 Subsequent N-alkylation with morpholine was achieved in DMF
at 100 °C folowed by cooling to room temperature to precipitate the desired product 7. Activation of the
pyrimidinone was accomplished with an adapted procedure using phosphorus oxychloride (POCl3) and
catalytic DMF in toluene to give the corresponding chloropyrimidine 8 as a brown oil in good yield. Finally,
8 was subjected to microwave assisted nucleophilic aromatic substitution with 3-(trifluoromethyl)aniline in
i-PrOH to afford the target compound 1, following chromatography and recrystallisation from chloroform.
Scheme 1. Chemical Synthesis of 1a
aReagents and conditions: (i) morpholine, 0-45 oC, 80%; (ii) chloroacetonitrile, 1,4-dioxane, HCl(g) (Kipp’s
apparatus), 50 oC, 2 h, 85%; (iii) DMF, morpholine, Et3N, 100 oC, 2 h, 80%; (iv) POCl3, toluene, 100 °C, 4 h,
75%; (v) i-PrOH, m-trifluoromethylaniline, MWI, 2 h, 70%.
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5Single Modifications to Fused Cyclohexane Moiety, 2-, and 4-Positions of 1. In addition to 1, we generated a
focused library of thieno[2,3-d]pyrimidine analogues bearing single structural modifications to examine the
effect on functional binding affinity and allosteric pharmacology of the scaffold (Figure 2). This included
modifying the fused ring system – initially observing the effect of differing ring size (fused cyclopentane 14a,
cycloheptane 14b and cyclooctane 14c) (Schemes 2 and 3), as well as the effects of removing substitution at
the 5- and 6-position of the thienopyrimidine 14j. Moreover, we explored functionalisation of both the 5- and
6-positions with various substituents (6-phenyl, 14d; 5-phenyl, 14e; 6-benzyl, 14f; 5-cyclohexyl, 14g; 5,6-
dimethyl, 14h; 6-cyclohexyl, 14i) (Scheme 3) to provide an understanding of the chemical space surrounding
this moiety for further future elaboration. We investigated the effect of removing the CF3 substituent on the
aryl ring 16a, and the influence of incorporating additional substituents with different electronic effects (3-F,
16b; 3-OCH3, 16c; 3-OH, 17) (Scheme 4). In addition to this, we explored the role of the secondary aliphatic
amine bridging the substituted aryl moiety in 1 through the synthesis of two analogues bearing N-methylamino
(18) and N,N-diethylamino (19) substituents (Scheme 4). The role of this secondary amine was further probed
through the removal of its hydrogen-bond donor property via isosteric replacement with an ether linkage (20)
(Scheme 4). This would permit the assessment and influence of hydrogen bond donor removal and any
subsequent functional effects on the allosteric pharmacology of 1. The N-methylamino derivative (18) would
test the importance of aromaticity whilst still maintaining hydrogen-bond characteristics of 1, while the N,N-
diethylamino analogue (19) investigates the impact of removing aromaticity and hydrogen-bond donor
properties at the 4-position. Additionally, the ether derivative (20) assesses the importance of removing
hydrogen-bond donor properties while maintaining aromaticity. We also focused on the 2-position of 1, where
we sought to evaluate the impact of removing the 2-morpholinomethyl moiety entirely (23a, Scheme 5),
subsequently conferring no substitution at the 2-position of the thienopyrimidine. In addition to this, we
investigated isosteric replacement of the morpholino O for CH2 to afford the piperidine analog 26 (Scheme 6),
as well as a similar replacement of N for CH to furnish the tetrahydopyran analog 33a (Scheme 7). Moreover,
we investigated the effects of increasing the methylene linker length bearing morpholine (ethylene, 39a;
propylene, 39b; butylene, 39c) (Scheme 8).
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6Figure 2. Areas of structural modification of 1 conducted during intial SAR investigation.
Hybrid Modification of 1. Several additional compounds were synthesised to further investigate the effects of
the aforementioned structural modifications. These modifications included deletion of the fused cyclohexane
system of the tricyclic scaffold, removal of the 2-morpholinomethyl pendant, isosteric replacement through
substitution of the morpholine ring for tetrahydropyran, and the incorporation of a 1,4-butylene linker; all
bearing the N,N-diethylamino functionality in place of the aryl m-CF3 moiety. These subsequent analogues
(23b, Scheme 5), (33b, Scheme 7), (40, Scheme 9), (44, Scheme 11) were synthesised as outlined previously
by varying the nature of the nucleophile used in the final nucleophilic aromatic substitution. Finally, a further
four analogues (43a-b, Scheme 10: 47a-b, Scheme 11), were synthesised to examine the effects of
simultaneous deletion/instalment of functionality with respect to maintaining one of either m-CF3-aryl or N,N-
diethylamino substituents at the 4-position of 1.
The thieno[2,3-d]pyrimidine moiety (Figure 2) is prevalent in a variety of reported compounds, thus
its synthesis is well established.17-22 Rapid access to a series of analogues substituted at the 5- and 6-positions
was achieved using the appropriate aldehyde or ketone as a starting material, by means of Gewald-type
chemistry (Scheme 2). An alternative method to traditional Gewald chemistry using solvent-free conditions
for the preparation of substituted 2-aminothiophene derivatives from respective ketones/aldehydes in the
presence of morpholine as catalyst was used to furnish a parallel set of analogues (Scheme 2).23 The
commercial availability of aldehydes (9d, 9f, 9i) or ketones (9a-c, 9e, 9g, 9h) and their usefulness in Gewald-
type chemistries or variations thereof permitted easy access to a variety of substituted thienocarboxylate
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7precursors 10a-i bearing a primary amine and ethyl ester as functional handles. Ethyl 2-aminothiophene-3-
carboxylate 10j, was obtained in accordance with an adapted procedure24 (Scheme 2) using the commercially
available mercaptoacetaldehyde dimer, 1,4-dithiane-2,5-diol (9j). This reagent was successfully used to afford
10j as a yellow crystalline solid in good yield.
Scheme 2. Chemical Synthesis of 2-Amino-3-Carbethoxythiophenesa
aReagents and conditions: (i) sulfur, abs. EtOH, ethyl cyanoacetate, 60 °C, 3-4 h, 50-80% (10a-c); (ii) sulfur,
morpholine (neat), ethyl cyanoacetate, r.t., ~18 h, 45-80% (10d-i); (iii) Et3N, ethyl cyanoacetate, DMF, 45 °C,
0.5 h, 55% (10j).
To allow construction of the 2-chloromethyl-substituted pyrimidine bearing a functional handle for further
elaboration, the appropriate thiophenes 10a-j were subjected to an intermolecular cyclisation reaction under
acidic conditions in the presence of chloroacetonitrile to afford the desired thieno[2,3-d]pyrimidine core which
could be utilised for further derivatisation (Scheme 3). Cyclisation required dry HCl gas to be generated in
situ (Kipps’ apparatus) and to be passed through a solution containing the respective nitrile and thiophene,
furnishing the corresponding 2-haloalkyl pyrimidinones 11a-j in high yields.16
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8Scheme 3. Chemical Synthesis of Analogues of 1 with Modifications to Fused Cyclohexane Systema
aReagents and conditions: (i) thiophene, chloroacetonitrile, HCl(g), 50 °C – reflux, 4-24 h, 20-95%; (ii) DMF,
Et3N, 100°C, 4-8 h, 50-90 %; (iii) POCl3, DMF(cat.), toluene, 3-5 h, 70-90%; (iv) 3-(trifluoromethyl)-aniline,
Et3N, i-PrOH, MWI, 1-3 h, 60-90%; (v) 15, DMF, 100°C, 33%.
N-Alkylation of morpholine with 11a-j was conducted in DMF and typically proceeded smoothly to provide
the corresponding morpholinomethyl analogues 12a-j. Products could often be precipitated with H2O, washed
with an appropriate solvent and/or recrystallised. Carbonyl activation was achieved through the use of POCl3
along with catalytic DMF in toluene to attain clean conversion to the corresponding chloropyrimidines (13a-
j). Finally, the appropriate chloropyrimidine (13a-j) could be taken up in i-PrOH and subjected to microwave-
assisted nucleophilic aromatic substitution in the presence of the appropriate nucleophile (primary aromatic
or secondary acyclic aliphatic amine) and an excess of Hünigs base to furnish target analogues 14a-j in good
yields. Initially, DMF was trialed as a potential reaction solvent for nucleophilic aromatic substitution,
however produced sub-optimal yields and by-products, and thus was not used further. Compound 15 was
isolated as a reaction by-product during the attempted synthesis of 14f, due to the presence of N,N-
dimethylamine existing as an impurity in DMF, thus it was characterised and tested for its in vitro activity.
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9Substituents at the thienopyrimidine 4-position. Compounds 16a-c were similiarly obtained as previously
outlined, through the use of various substituted anilines via nucleophilic aromatic substitution with key
chloropyrimidine intermediate 8 (Scheme 4). Compound 16c was used to access the phenolic analogue via O-
demethylation employing boron tribromide in DCM at 0 ºC to afford the corresponding phenol 17 in good
yield. To assess the impact of removing aromaticity from the 4-position, several additional analogues of 1
were synthesised (Scheme 4). To do this, key intermediate 8 was again subjected to nucleophilic aromatic
substitution using an excess of N-methyl or N,N-diethylamine under basic conditions in i-PrOH which
furnished the corresponding N-methylamino and N,N-diethylamino analogues in good yields as light brown
oils (18 & 19, respectively). To advance our understanding of the aniline’s role within 1, we generated a
compound deficient of a hydrogen-bond donor group through isosteric replacement with an ether linkage but
still bearing the aryl-CF3 substituent (20, Scheme 4). To achieve this compound 8 was subjected to MWI in
the presence of 3-(trifluoromethyl)phenol and a 10% molar equivalent of phase-transfer catalyst tris[2-(2-
methoxyethoxy)ethyl]amine (TRIDENT). Subsequent chromatographic purification afforded the target ether-
derivative 20 as a transparent oil in 72% yield.
Scheme 4. Synthesis of Analogues Modified at the 4-Positiona
aReagents and conditions: (i) substituted aniline, iPrOH, MWI, 2 h, 65-90% (16a-c); (ii) BBr3 (1 M in DCM),
r.t., overnight, 53% (17); (iii) i-PrOH, methylamine, MWI, 140 °C, 2.5 h, 85% (18); i-PrOH, N,N-
diethylamine, MWI, 140 °C, 3 h, 91% (19); i-PrOH, 3-(trifloromethyl)phenol, TRIDENT(cat.), MWI, 6 h, 72%
(20).
Substituents at the thienopyrimidine 2-position. To assess the effects of removing the 2-
morpholinomethyl moiety (Scheme 5), 4,5,6,7-tetrahydrobenzothiophene 5 was refluxed for several hours in
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10
neat formamide to construct the corresponding pyrimidinone 21. This compound was similarly converted to
4-chloro analogue 22, followed by nucleophilic aromatic substitution with 3-(trifluoromethyl)aniline to yield
compound 23a (Scheme 5). To further assess the effect of introducing an N,N-diethylamino substituent at the
4-position of 1, we synthesised an additional analogue that incorporated this amine in conjunction with
removal of the 2-morpholinomethyl substituent (23b, Scheme 5). This compound was accessed using key
intermediate 22 via nucleophilic aromatic substitution thereby permitting us to further probe the effect of
incorporating an aliphatic 4-substituent but still bearing similar hydrogen-bonding capabilities.
Scheme 5. Chemical Synthesis of Analogues of 1 devoid of Morpholinomethyl Moietya
aReagents and conditions: (i) formamide, 170 °C, 12 h, 85%; (ii) POCl3, DMF(cat.), toluene, 100 °C, 3-5 h,
90%; (iii) i-PrOH, m-CF3-aniline, DIPEA, MWI, 2 h, 75% (23a); (iv) i-PrOH, Et2NH, DIPEA, MWI, 2 h,
90% (23b).
Next, we focused on the morpholine moiety to probe the effect on the allosteric pharmacology of 1 by
replacing the O or N heteroatoms with a methylene or methine group to give piperidine analogue, 26 and
tetrahydropyran analogue, 33a, respectively. Compound 26 (Scheme 6) was accessed via the N-alkylation of
piperidine with key intermediate 6, again followed by chlorination (25) and substitution to afford 26 in good
yield. Compound 33a (Scheme 7) was furnished via a multi-step synthesis that initially involved activation of
diethyl cyanomethylphosphonate 28 with NaH, followed by drop-wise addition of tetrahydro-4H-pyran-4-one
27 in diethyl ether. Vacuum distillation and recrystallisation from petroleum-ether afforded the corresponding
nitrile 29 as a transparent crystalline solid in moderate yield. Catalytic hydrogenation employing Pd/C as
catalyst in EtOAc and AcOH under atmospheric pressure gave the corresponding saturated nitrile 30 as a
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11
transparent oil in high purity. Intermolecular cyclisation of thiophene 5 with 30 proceeded in 1,4-dioxane
under standard acidic conditions (Kipp’s apparatus) to afford the thienopyrimidinone 31, though requiring
reflux temperatures to achieve full conversion. Subsequent DMF-catalysed POCl3 activation in toluene
provided the chloropyrimidine 32, followed by nucleophilic aromatic substitution in i-PrOH to afford the
target tetrahydropyran 33a as a white foam in moderate yield. To better assess the effects of N,N-diethylamino
substitution of the 4-position in combination with the tetrahydropyran functionality, one additional analogue
was synthesised (33b). This compound was readily accessed by reacting the appropriate starting material 32
under standard conditions to afford the target as a light gold oil in good yield (Scheme 7).
Scheme 6. Chemical Synthesis of Piperidine Analoguea
aReagents and conditions: (i) piperidine, Et3N, 100 oC, 2 h, 71%; (ii) toluene, 100 °C 4 h, 46%; (iii) i-PrOH,
m-trifluoromethylaniline, MWI, 2 h, 70%.
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12
Scheme 7. Chemical Synthesis of Tetrahydro-2H-pyran-4-yl Analogues of 1a
aReagents and conditions: (i) Et2O, 0 °C - r.t. 24 h, 39%; (ii) 10% Pd/C, EtOAc, AcOH, 1 atm, r.t. 5 h, 100%;
(iii) 1,4-dioxane, HCl(g), r.t. – reflux, 13 h, 93%; (iv) toluene, POCl3, DMF(cat.), 100 °C, 4 h, 24%; (v) amine,
i-PrOH, MWI 120 °C, 3 h, 48% (33a); (vi) i-PrOH, Et2NH, MWI, 120 °C, 2 h, 85% (33b).
Chain-extension of the 2-substituent linker of 1. To investigate the effects of increasing the methylene linker
length on the allosteric pharmacology of 1, we generated a series of analogues of differing methylene chain
length (2-4) bridging the morpholine substituent to the pyrimidine core (Scheme 8). Commercially available
primary chloroalkyl nitriles: 3-chloropropionitrile 34a, 4-chlorobutanenitrile 34b and 5-chloropentanenitrile
34c, were reacted in the presence of thiophene 5 under standard acidic conditions in order to furnish the
corresponding chain-extended pyrimidinones (36a-c). These nitriles were substantially less reactive than
chloroacetonitrile, and thus required reflux temperatures to complete the conversion of the amidinium species
formed in situ to the corresponding 2-chloro-pyrimidinone.
Using standard conditions, alkylation of morpholine with the appropriate chain extended chloro-pyrimidinone
was attempted to generate the corresponding morpholinoethyl, morpholinopropyl, and morpholinobutyl
substituted intermediates 37a-c. This methodology successfully afforded the morpholinoethyl pyrimidinone
37a in good yield as a yellow crystalline solid (Scheme 8), however pyrimidinone derivatives bearing the
longer chloroalkyl chains were suspected to be eliminating under basic conditions. 1H NMR analysis provided
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13
confirmation of favoured intramolecular cyclisation under both ambient and reflux conditions, generating two
tetracyclic regioisomers in a 1:1 ratio.25 In light of this, additional efforts focused on construction of the N-
substituted nitrile moiety first (Scheme 8). This was accomplished by stirring the appropriate nitrile (34a-c)
with an excess of morpholine in refluxing toluene for several hours to furnish the corresponding N-morpholino
nitriles (35a-c) in good yields as transparent oils. These intermediates were reacted with 5 under acidic
conditions to afford the target morpholinopropyl and morpholinobutyl pyrimidinones in good yields (37b-c)
followed by chlorination (38a-c) and subsequent nucleophilic aromatic substitution to furnish the final chain
extended analogues 39a-c.
Scheme 8. Synthesis of Morpholino-Substituted Nitriles and Corresponding Alkyl Chain-Extended
Analogues of 1a
aReagents and conditions: (i) morpholine, toluene, reflux, 7 h, 45-65% (35a-c); (ii) 1,4-dioxane, nitrile, HCl
(g), r.t. 12 h, reflux 4 h, 57-80% (37b-c); (iii) 34a-c, 1,4-dioxane, HCl(g), r.t. 12 h – reflux 3 h, 60-83% (36a-
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c); (iv) DMF, 50 °C, 4 h, 56% (37a); (v) POCl3, toluene, DMF(cat.), 2-5 h, 67-88% (38a-c); (vi) NaH, 3-
(trifluoromethyl)aniline, DMF, 100 °C, 6 h, 27% (39a); (vii) i-PrOH, MWI, 2-4 h, 56-59% (39b-c).
Hybrid Functionalisation of 2- and 4-positions of 1. The subsequent pharmacological effects of incorporating
extended morpholinoalkyl substituents into analogues of 1 (39a-c) conveyed interesting changes in the
functional properties of this scaffold. The 1,4-butylene linker was of particular interest. Thus, compound 40
was synthesised using intermediate 38c (Scheme 9) via nucleophilic aromatic substitution to enhance our
understanding of the SAR surrounding the 4-position of 1 with respect to N,N-dimethylamino substitution. In
addition to further investigate the 1,4-butylene linker, removal of the fused functionality within 1 (14j) resulted
in a loss of not only binding affinity, but rendered this analogue functionally inactive. To this end, we sought
to investigate the effect of removing the fused cyclohexane system whilst maintaining the morpholinobutyl
functionality in conjunction with one of either 3(trifluoromethyl)anilino or N,N-diethylamino substitutents at
the 4-position (Scheme 10). These two additional analogues were accessed by reacting the appropriate
unsubstituted thiophene 10j with 35c under acidic conditions to provide cyclised product 41, followed by
chlorination 42 and nucleophilic aromatic subsitution employing conditions as outlined previously to furnish
43a-b in good yields (Scheme 10).
Scheme 9. Synthesis of N,N-Diethylamino Analogue Bearing Morpholinobutyl Substitutent & Fused
Cyclohexane Moietya
aReagents and conditions: (i) i-PrOH, Et2NH, MWI, 120 °C, 3 h, 85%
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Scheme 10. Further Analogues of 1 Bearing the Morpholinobutyl Substituenta
aReagents and conditions: (i) 1,4-dioxane, HCl(g), r.t overnight, reflux 3-6 h, 57-65%; (ii) toluene, POCl3,
DMF(cat.), 3 h, 60-88% (iii) i-PrOH, Et2NH, MWI, 120 °C, 1.5 h, 80% (43a); i-PrOH, Et2NH, MWI, 120 °C,
4 h, 90% (43b).
In addition to this, we wanted to observe the effects of N,N-diethylamino substitution of 14j as a direct
comparison with 3-(trifluoromethyl)aniline. Thus, 13j, whose synthesis is depicted in Scheme 3, was reacted
with N,N-diethylamine under microwave irradiation to afford 44 in good yield (Scheme 11). Moreover, we
wanted to observe the effect of aromatic and aliphatic substituents at the 4-position of 1 in conjunction with
concurrent removal of the fused cyclohexane and morpholinomethyl moieties. Removal of said functionalities
on the structure of 1 effectively results in a low molecular weight fragment-like core. These compounds were
readily accessed using chemistry as outlined previously (Scheme 11) to furnish the target analogues 47a-b in
high yields.
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Scheme 11. Further Thieno[2,3-d]pyrimidin-4-amine Analogues of 1a
aReagents and conditions: (i) Et2NH, DIPEA, i-PrOH, MWI, 120 °C 1.5 h, 94% (44); (ii) formamide, 170 °C,
6 h, 76%; (iii) toluene, POCl3, DMF(cat.), 3 h, 88%; (iv) m-CF3-aniline, DIPEA, i-PrOH, MWI, 120 °C 2.5 h,
80% (47a); Et2NH, DIPEA, i-PrOH, MWI, 120 °C 1.5 h, 90% (47b).
Pharmacology. Confirmation of an allosteric mode of action for 1 at the D2R. Our previous study predicted
that 1 can adopt an allosteric pose within the D3RAPO model and revealed that this compound also displayed
activity at the D2R, our primary target of interest.8 Prior to initiating an investigation into 1, we wanted to
confirm its activity at the D2R, and determine if it displays competitive or allosteric pharmacology.
Equilibrium radioligand binding experiments were performed on 1 to monitor its effect upon orthosteric ligand
([3H]raclopride) binding in membranes prepared from FlpIn CHO cells stably expressing the long isoform of
the human D2R (hD2LR).26 This assay may also provide indication of an allosteric versus competitive mode of
action. If the compound displays incomplete or partial displacement of the radioligand this is consistent with
the saturable effect of an allosteric modulator whereby the degree of negative cooperativity with the
radioligand detemines the level of radioligand displacement. In cases where one observes only partial
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displacement, data may be fit using an allosteric ternary complex model to derive a value of affinity, denoted
as KB, and cooperativity with [3H]raclopride (α).27 However, in our assay, 1 was able to completely displace
[3H]raclopride. Therefore, this assay did not allow us to discriminate between high negative cooperativity with
the [3H]raclopride or competition for the orthosteric binding site (Table 1). Thus, to determine evidence of an
allosteric mode of action for this ligand, we extended our evaluation to measurements of [3H]raclopride
dissociation from the D2R (Figure 3A). Dissociation of the radioligand was measured following addition of a
high concentration of cold orthosteric ligand (10 µM haloperidol) to prevent [3H]raclopride rebinding in the
absence or presence of 1. In the presence of 100 µM of 1, the dissociation rate of [3H]raclopride from the D2R
significantly increased, (Table 2 and Figure 3A) consistent with 1 binding to an allosteric site within the D2R.28
Our pharmacological analysis using the above radioligand binding assay did not provide information
regarding the modulatory effect of 1 upon the neurotransmitter dopamine. Therefore, we tested 1 in an assay
measuring inhibition of forskolin-stimulated cyclic adenosine monophosphate (cAMP) accumulation through
activation of the hD2LR stably expressed in FlpIn CHO cells using a BRET biosensor.29 The concentration-
dependent response of dopamine was measured in the presence of increasing concentrations of 1 and 10 μM
forskolin. Application of an operational model of allosterism to the concentration-response data yielded an
estimate of affinity of 1 for the unoccupied receptor (KB), and its cooperativity with dopamine where α is
cooperativity exerted upon dopamine binding, and β denotes modulation of dopamine efficacy.30 These data
are reported in Table 4 and are presented as logarithms to base 10 to allow statistical comparison.31 Values of
α or β < 1 signify negative cooperativity with dopamine. The lead compound 1 acted as a negative allosteric
modulator at the D2R, with low µM functional affinity (KB = 3.9 µM). The depression in the maximal response
upon the dopamine dose-response curve caused by increasing concentrations of 1 is characteristic of the action
of a NAM of agonist efficacy (Figure 3B). In order to fit these data, the cooperativity of 1 with dopamine
affinity (α) was constrained to be neutral, allowing us to estimate a value of modulatory action upon dopamine
efficacy (β = 0.28) that equates to a maximal 3-fold decrease (Figure 3B, Table 4). This action is different to
the action of the competitive antagonist haloperidol at the D2R that acts to cause a dextral shift in the dopamine
dose-response curve with no affect upon the maximal effect of dopamine (Figure 3C). Thus, by using
complementary pharmacological approaches including equilibrium and dissociation kinetic binding analyses,
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together with experiments measuring D2 receptor function, we have confirmed that 1 acts through a non-
competitive mechanism to modulate the activity of dopamine at the D2R i.e. it is NAM of the efficacy of
dopamine. The thienopyrimidine scaffold of 1 is unique to known dopaminergic receptor ligands. Therefore,
a novel allosteric scaffold for the D2R has been identified and validated. Moreover, further validation has been
provided for virtual allosteric ligand screening at the dopamine D2-like receptors.
Figure 3. Compound 1 displays allosteric pharmacology at the D2R. (A) 1 acts to increase the rate of
dissociation of [3H]raclopride from the hD2LR expressed in FlpIN CHO membranes consistent with an
allosteric mode of action (Table 2). (B) In an assay measuring inhibition of forskolin-stimulated cAMP
production using a BRET biosensor, 1 acts to cause limited depression in the maximal response of dopamine
with more modest effects upon dopamine potency (these data were fitted with an operational model of allostery
to derive values of affinity and cooperativity, Table 4). In constrast increasing concentrations of haloperidol
(C) causes a limitless dextral shift in dopamine potency with no effect on dopamine maximal response
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consistent with competitive antagonism and can be fit with a Gaddum-Schild model to derive a value of affnity
pA2 = 9.67 ± 0.10. Data is the mean ± SEM of three independent experiments performed in duplicate.
Radioligand binding analysis of analogues of 1: To begin to explore the structural features of 1 that determine
its allosteric activity, we employed the equilibrium [3H]raclopride binding assay described in our
characterisation of 1 above. For the majority of compounds, we observed complete displacement of the
radioligand. Therefore, while this simple assay provides us with both confirmation of target activity and a
value of affinity, for these compounds, we cannot distinguish between a competitive mode of interaction or
an allosteric interaction that exerts high negative cooperativity upon [3H]raclopride binding. We first
examined modifications to the fused cyclohexane system of 1 (Table 1). Replacement of the 6-membered
saturated ring with a fused cyclopentane (14a) or cycoheptane (14b) system made no significant impact on
binding affinity. However, replacement with the cyclooctane (14c) system caused a significant 6-fold decrease
in affinity. No significant effect on affinity was seen when various other substituents were introduced to the
5- and 6-positions of the thienopyrimidinone (14d-g, i). Conversely, introduction of the 5-phenyl substituent
(14e) did result in an apparent decrease in negative cooperativity manifested by an incomplete displacement
of [3H]raclopride that allowed us to determine a value of cooperativity, α = 0.13 (Table 1). 5,6-Dimethyl 
substitution (14h), as well as removal of the fused system (14j) both caused a significant 5-10-fold decrease
in affinity (KB = 250 and 120 µM, respectively). To further explore the role of the N-(3-
(trifluoromethyl)phenyl) substituent of 1, we generated a small series of analogues of 1 that incorporated
changes to this functionality, including removal of the CF3 substituent (16a), as well as substitution with
various groups (3-F, 16b), (3-OCH3, 16c), (3-OH, 17). Removal of the CF3 substituent caused a 6-fold decrease
in affinity whereas both the 3-OH and 3-OMe analogues displayed similar affinity to the parent compound
(1). To investigate the effects of removing the N-(3-trifluoromethyl)phenyl substituent at the 4-position, we
synthesised a series of analogues of 1 that included an N,N-dimethylamino group (15) that was isolated as a
by-product from the synthesis of 14f as a result of trialing DMF as a reaction solvent, as well as analogues
bearing N-methylamino (18), and N,N-diethylamino (19) moieties. In addition to this, we investigated the
effect of removing the secondary amine bridging the aryl moiety to the pyrimidine moiety of 1 by isosteric
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replacement with an ether linkage (20). These analogues all saw no significant change in affinity as compared
to 1. Interestingly, however, 19 displayed only partial displacement of [3H]raclopride at the D2R (KB = 6.0
µM, α = 0.23) (Table 1, Figure 4A). These data demonstrate that the secondary amine plays no role in the
functional affinity of 1, but modification of this feature can modulate the negative cooperativity with
[3H]raclopride. Additional analogues were synthesised to examine the effect of increasing the methylene
linker length bearing the morpholine substituent (39a-c), as well as the effect of replacing either the oxygen
or nitrogen atoms within morpholine with CH2 and CH (26 & 33a, respectively, Table 1). Of note, the addition
of a morpholinobutyl substituent (39c) not only appeared to increase affinity 5-fold but also to cause an
apparent decrease in negative cooperativity such that this compound was only able to partially inhibit the
binding of [3H]raclopride (α = 0.09). Interestingly, while incorporation of piperidine 26 saw no changes in
affinity, the tetrahydropyran analogue 33a lost affinity and apparent negative cooperativity with
[3H]raclopride as the highest concentration of 33a only partially displaced the radioligand from the receptor
(KB = 100 µM, α = 0.39) (Table 1, Figure 4A). Similarly, removal of the morpholinomethyl moiety 23a did
not affect binding affinity despite having effects on negative cooperativity with only partial displacement the
radioligand again observed (KB = 31 µM, α = 0.39) (Table 1, Figure 4A). In summary, the removal of the
morpholinomethyl moiety, or incorporation of N,N-diethylamino, tetrahydropyranomethyl, and
morpholinobutyl functionalities yielded ligands that exhibited incomplete displacement of [3H]raclopride,
suggesting that these functionalities were important determinants of cooperativity (compounds 23a, 19, 33a,
and 39c, respectively). Accordingly, analogues were synthesised integrating these changes with additional
structural changes (Table 1). We synthesised four analogues combining the incorporation of the N,N-
diethylamino moiety into these novel analogues of 1, including 23b (morpholinomethyl deletion), (33b)
(tetrahydropyranomethyl), 40 (morpholinobutyl), and (44) (fused cyclohexane deletion). In addition to these
modifications, we wanted to examine the effects of bis-functionalisation with respect to incorporating m-
trifluoromethylaniline or N,N-diethylamine. We synthesised two compounds devoid of the fused cyclohexane
system and morpholinomethyl moieties but maintained substitution with one of either m-
trifluoromethylaniline or N,N-diethylamine, to reveal fragment-like low molecular weight analogues (47a &
47b respectively). While both maintained affinity at the D2R, the latter compound was only able to partially
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displace [3H]raclopride and a value of α = 0.10 could be determined reflecting moderate negative
cooperativity. Excitingly, our finding that 47a and 47b, analogues both devoid of the fused system and
morpholinomethyl moieties that maintain affinity, indicate that the scaffold of 1 can be ‘pruned back’ to reveal
modulators of the D2R with low molecular weights and high ligand efficiencies. A further two compounds
were synthesised that comprised the morpholinobutyl moiety but were devoid of the fused cyclohexane
system, and were substituted with either m-trifluoromethyl-aniline or N,N-diethylamine (43a & 43b
respectively). Affinity was maintained for these analogues showing that the fused cyclohexane may be
removed from the scaffold without detriment. It is interesting to note that 44 displayed 100-fold improved
affinity (KB = 1 µM) from its parent analogue 14j (KB = 120 µM), demonstrating the N-N-diethylamino
substituent is favourable over the m-trifluoromethyl substituted aryl system. Similarly, upon introduction of
this amine to 33a, compound 33b gained a 3-fold improvement in affinity (KB = 35 µM), but acted to
completely displace [3H]raclopride suggestive of higher negative cooperativity or a competitive mode of
interaction. This is consistent with our observation that, while 23a partially displaced [3H]raclopride,
compound 23b was able to completely displace the radioligand. In summary, then, our exploration of the
thienopyrimidine scaffold of 1 revealed that a vast array of modifications are tolerated in terms of affinity for
the D2R but that subtle modifications to the 4-position may modulate the degree of negative cooperativity
between the allosteric ligand and orthosteric probe [3H]raclopride. As the degree of negative cooperativity on
[3H]raclopride binding significantly changed upon N,N-diethylamino substitution (19), resulting in the
incomplete displacement of the radioligand, we sought to obtain additional confirmation of an allosteric mode
of interaction. The profile of 19 was further explored through radioligand binding dissociation kinetic
experiments. In the presence of 19, the dissociation rate of the [3H]raclopride from the D2R again significantly
increased (Table 2). This experiment provided further validation of the allosteric mode of action of 1 and its
structural analogues.
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Figure 4. Analogues of 1 act to partially displace orthosteric radioligand binding at the D2R and D3R.
(A) In equilibrium radioligand binding experiments, 1 acts to completely displace [3H]raclopride from the
hD2LR expressed in FlpIN CHO membranes, an effect consistent with a competitive mode of binding or an
allosteric mode of binding that exerts high negative cooperativity with [3H]raclopride (Table 1). In contrast
compounds 19, 23a, and 33a act to only partially displace [3H]raclopride at the highest concentration
consistent with an allosteric mode of action and moderate negative cooperativity (these data were fitted with
an allosteric ternary complex model to derive estimates of affinity (KB) and cooperativity with [3H]raclopride
(α), Table 1). (B) 1 acts to partially displace [3H]raclopride from the hD3R expressed in FlpIN CHO
membranes at the highest concentration measured, whereas 19 completely displaces [3H]raclopride from the
D3R (Table 3). Data is the mean ± SEM of three independent experiments performed in duplicate.
Page 22 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23
Table 1. Ability of 1 and derivatives of 1 to displace the radiolabelled antagonist [3H]raclopride at the
D2LR expressed in FlpIn CHO cells.
n R1 R2 R3 R4 pKB(KB, µM)a
Log α  
(α) b
1 2 - - 4.78 ± 0.11 (16.6) -
14a 1 - - 4.23 ± 0.12 (59) -
14b 3 - - 4.43 ± 0.21 (37) -
14c 4 - - 3.98 ± 0.17 (106) -
14d - H 4.35 ± 0.13 (45) -
14e - H 4.31 ± 0.11 (48.6) -0.88 ± 0.10 (0.13)
14f - H 4.30 ± 0.18 (50) -
14g - H 4.42 ± 0.20 (38) -
14h - CH3 CH3 3.59 ± 0.15 (250) -
14i - H 4.34 ± 0.18 (45.8) -
14j - H H 3.91 ± 0.20 (120) -
15 - H N(CH3)2 4.51 ± 0.14 (30) -
16a 2 - - 4.00 ± 0.16 (99) -
16b 2 - - nd nd
16c 2 - - 4.32 ± 0.14 (48) -
17 2 - - 4.45 ± 0.10 (35) -
O
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N HN CF3
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N HN CF3
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18 2 - - NCH3 4.28 ± 0.11 (53) -
19 2 - - N(CH2CH3)2 5.22 ± 0.16 (6) -0.64 ± 0.06 (0.23)
20 2 - - 4.66 ± 0.12 (22) -
23a 2 - - H 4.51 ± 0.13 (31) -0.41 ± 0.04 (0.39)
23b 2 - - H N(CH2CH3)2 4.76 ± 0.07 (17) -
26 2 - - 4.41 ± 0.12 (39) -
33a 2 - - 3.99 ± 0.27 (100) -0.41 ± 0.08 (0.39)
33b 2 - - N(CH2CH3)2 4.45 ± 0.09 (35) -
39a 2 - - 4.16 ± 0.16 (70) -
39b 2 - - 4.89 ± 0.17 (13) -
39c 2 - - 5.48 ± 0.09 (3.31) -1.03 ± 0.09 (0.09)
40c 2 - - N(CH2CH3)2 4.79 ± 0.08 (16) -
43a - H H 4.71 ± 0.09 (19) -
43b - H H N(CH2CH3)2 5.51 ± 0.11 (3) -
44 - H H N(CH2CH3)2 5.89 ± 0.09 (1.3) -
47a - H H H N(CH2CH3)2 4.20 ± 0.09 (63) -
47b - H H H 4.65 ± 0.12 (23) -1.01 ± 0.14 (0.10)
aEstimate of the negative logarithm of the equilibrium dissociation constant ± SEM determined by radioligand binding.
bEstimate of the logarithm of the net cooperativity factor between the modulator and [3H]raclopride. Values represent
the mean ± SEM from at least three experiments performed in duplicate.
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Table 2. Compounds 1 and 19 act to increase the rate of [3H]Raclopride dissociation from membrane
homogenates of FlpIn CHO Cells Stably Expressing the D2LR.b
Values represent the mean ± S.E.M. from at least three independent experiments performed in quadruplicate. *Analysis
with a student’s t-test revealed that [3H]raclopride displayed a significantly higher (p < 0.05) koff in the presence of
haloperidol plus modulator as compared to haloperidol alone.
Finally, we sought to assess receptor sub-type selectivity at the D3R versus the D2R; accordingly,
equilibrium radioligand binding experiments were conducted on 1 and a further seven structural analogues
(19, 23a, 33a, 39c, 40c, 43b and 44, Table 3). Molecules were selected based upon their profiles at the D2R
acquired from [3H]raclopride binding experiments at this receptor, where some showed increased binding
affinites and divergent cooperativity profiles. Interestingly, two compounds displayed selectivity for the D2R
over the D3R 39c (30-fold selectivity) and 44 (10-fold selectivity). In contrast, compounds 1, 19 and 23a
displayed selectivity towards the D3R (57-fold, 23-fold, 140-fold, respectively). All other compounds
displayed no significant subtype selectivity (33a, 40, 43b). It is interesting to note that many compounds
assayed at the D3R saw strikingly different levels of negative cooperativity with [3H]raclopride binding
compared to that observed at the D2R (Table 3, Figure 4B). For example, at the D2R, 19 only partially displaces
[3H]raclopride at the highest concentration measured, however, at the D3R it completely displaces
[3H]raclopride at the highest concentration despite having a lower functional binding affinity (KB = 89.7 µM)
(Table 3, Figure 4B). As 1 was identified via virtual ligand screening using a D3R crystal structure, it is
unsurprising that 1 displayed subtype selectivity for this receptor. However, our study has identified D2R-
selective compounds that may be used as a starting point for the future development of D2R subtype-selective
ligands.
koff (min-1) t1/2 (min)
haloperidol haloperidol +modulator haloperidol
haloperidol +
modulator
1 a0.020 ± 0.004 a0.038 ± 0.005* a 34.2 a 18.1
19 0.014 ± 0.001 0.038 ± 0.003* 49.2 18.2
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Table 3. Ability of 1 and derivaitives of 1 to displace the radiolabelled antagonist [3H]raclopride at the
D3R expressed in FlpIn CHO cells
aEstimate of the negative logarithm of the equilibrium dissociation constant ± SEM determined by radioligand binding.
bEstimate of the logarithm of the net cooperativity factor between the modulator and [3H]raclopride. Values represent
the mean ± SEM from at least three independent experiments performed in duplicate.
Functional Analysis (cAMP) of analogues of 1. We extended our characterisation of these compounds to their
effect upon dopamine action in the cAMP assay described above. Interestingly, all compounds above were
shown to retain activity in our equilibrium radioligand binding experiments, yet many failed to have any
effects upon dopamine binding and/or signalling efficacy within the same concentration range. This
observation is likely an example of probe dependence whereby these ligands exert negative cooperativity on
raclopride binding but display neutral cooperativity upon dopamine binding and efficacy. In agreement with
this hypothesis, while our binding assay found that 1 displayed a robust effect upon [3H]raclopride binding,
R1 R2
bpKB
(KB, µM)
D2/D3
selectivity
alog α
(α)
1 6.54 ± 0.27 (0.3) 57 -0.40 ± 0.04 (0.39)
19 N(CH2CH3)2 3.85 ± 0.16 (140) 23 -
23a H 6.65 ± 0.21 (0.2) 140 -0.39 ± 0.03 (0.06)
33a 4.28 ± 0.23 (52) 2 -0.44 ± 0.23 (0.37)
39c 3.97 ± 0.18 (106) 0.03 -0.69 ± 0.20 (0.20)
40 N(CH2CH3)2 4.99 ± 0.05 (10) 1.6 -
43b N(CH2CH3)2 6.06 ± 0.03 (0.9) 3.5 -
44 N(CH2CH3)2 4.95 ± 0.06 (11) 0.1 -
O
N HN CF3
O
N
HN CF3
O
HN CF3
O
N
4
HN CF3
O
N
4
O
N
4
O
N
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our functional data suggests that 1 acts to modulate dopamine efficacy but has little effect upon dopamine
affinity.
We first examined modifications to the 5,6-fused cyclohexane system of 1 (Table 4). We found that
increasing the fused ring size greater than 6-carbons renders these analogues inactive in this functional assay
(14b-c), while the five-membered cyclopentane system (14a) maintained functional affinity (KB = 11.4 µM)
but changed the nature of the cooperativity whereby we observed a modulatory effect on dopamine affinity (α
= 0.13) rather than modulation of efficacy (β = 1). Both 6-phenyl substitution (14d) and modifications to the
5-position with phenyl (14e) or cyclohexyl (14g) substituents resulted in a loss of activity. Activity was
maintained for the 6-cyclohexyl substituted analogue (14i, KB = 5.4 µM, Figure 5A), but in contrast to the
action of 1 that modulates dopamine efficacy, this ligand acted to modulate dopamine affinity only (α = 0.13)
(Table 4, Figure 5A). 5,6-Dimethyl substitution (14h), as well as removal of the fused functionality entirely
(14j), rendered these analogues inactive in our functional assays, thus indicating a small window in which 1
can be modified surrounding the 5,6-positions and still maintain allosteric pharmacology with dopamine.
Removal of the CF3 substituent on the aryl ring of 1 (16a, Table 5) or replacement with 3-F (16b), 3-OMe
(16c) or 3–OH (17) had no effect upon functional affinity. However, the addition of methoxy or hydroxy
substituents resulted in additional modulatory effects upon dopamine affinity (α = 0.19 and α = 0.06 
respectively).
Page 27 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28
Figure 5. Exporation of the thieno[2,3-d]pyrimidine scaffold of 1 reveals small molecule modulators of
the D2LR with distinct functional effects. (A) Modification of the 5,6-fused system in the form of a 6-
cyclohexane substitution (14i, Table 4) resulted in negative cooperativity upon dopamine affinity with no
effect upon dopamine efficacy (B). Replacement of the phenyl ring of 1 with N,N-diethyl (19, Table 6) caused
a 6-fold increase in affinity and 4-fold increase in negative cooperativity with dopamine. (C) Removal of the
morpholinomethyl moiety along with incorporation of the N,N-diethylamino substitution (23b, Table 7)
maintained affinity but resulted in a large increase in negative cooperativity with dopamine efficacy. (D)
Remarkably, a fragment-like derivative devoid of both the morpholinomethyl and fused cyclohexane moieties
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but incorporating the N,N-diethylamino substitution (47b, Table 8) maintained functional affinity and
displayed robust negative cooperativity with dopamine efficacy. All data are the mean ± SEM of three
independent experiments performed in duplicate. Data were fit using the operational model of allostery to
derive estimates of affinity and cooperativity with dopamine.
Table 4. Functional Parameters for Analogues of 1 with Chemical Modifications to the 5,6-Fused
System Derived from cAMP BRET Assay
n R1 R2
apKB
(KB, µM)
bLog α
(α)
cLog β
(β)
1 1 --
-
- 5.41 ± 0.22 (3.87) = 0 -0.55 ± 0.08 (0.28)
14a 2 - - 4.95 ± 0.40 (11.4) -0.90 ± 0.32 (0.13) = 0
14b 3 - - nd
14c 4 - - nd
14d - H nd
14e - H nd
14f - H nd
14g - H nd
14h - CH3 CH3 nd
14i - H 5.27 ± 0.17 (5.37) -0.90 ± 0.11 (0.13) = 0
14j - H H nd
aEstimate of the negative logarithm of the equilibrium dissociation constant determined in an cAMP functional assay.
bEstimate of the logarithm of the net cooperativity factor between the modulator and dopamine. cEstimate of the
logarithm of the modulatory effect upon efficacy factor induced by the allosteric modulator. nd = inactive at
concentrations up to 100 µM. Values represent the mean ± S.E.M. from at least three independent experiments
performed in duplicate.
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Table 5. Functional Parameters for Analogues of 1 with Modifications to Aryl Moiety
aEstimate of the negative logarithm of the equilibrium dissociation constant determined in an cAMP functional assay.
bEstimate of the logarithm of the net cooperativity factor between the modulator and dopamine. cEstimate of the
logarithm of the modulatory effect upon efficacy factor induced by the allosteric modulator. nd = inactive at
concentrations up to 100 µM. Values represent the mean ± S.E.M. from at least three independent experiments
performed in duplicate.
We then focused on the importance of the aryl ring within 1 by replacing the phenyl ring with acyclic aliphatic
amines (Table 6). These analogues still maintained a hydrogen-bond donor-acceptor, but lacked the aromatic
moiety in this region. The N-methylamino analogue (18) was inactive whereas the N,N-diethylamino analogue
(19) saw a 6-fold increase in functional affinity and a 4-fold increase in negative cooperativity with dopamine
efficacy (KB = 660 nM, β = 0.08, Figure 5B). To further probe the effects of this substituent, we tested an
additional analogue of 19 in which the fused cyclohexane system was removed entirely whilst maintaining
the N,N-diethyl functionality (44). While the analogue bearing no substitution at the 5- and 6-position (14j)
displayed no activity in this functional assay, to our surprise compound 44 maintained affinity (KB = 3 µM)
as well as robust negative cooperativity with dopamine affinity and efficacy (α = 0.08, β = 0.24). Interestingly,
due to the presence of the N,N-dimethylamino functionality, 6-benzyl substitution (15) no longer rendered the
molecule inactive, as seen previously with 14f (Table 4), but instead, caused affinity and negative allosteric
cooperativity to be maintained (Table 6). Together, these data demonstrate that the nature of the 4-substituent
(aromatic or acyclic aliphatic amine) has significant effects upon negative cooperativity with dopamine.
X apKB (KB, µM) bLog α (α) cLog β (β)
1 CF3 5.41 ± 0.22 (3.87) = 0 -0.55 ± 0.08 (0.28)
16a H 5.13 ± 0.31 (7.46) = 0 -0.95 ± 0.24 (0.11)
16b F 5.08 ± 0.44 (8.39) = 0 -0.40 ± 0.11 (0.40)
16c OMe 5.10 ± 0.13 (8.02) -0.73 ± 0.16 (0.19) -0.53 ± 0.14 (0.29)
17 OH 5.55 ± 0.12 (2.81) -1.22 ± 0.16 (0.06) -3.0
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Isosteric replacement of the secondary amine with an ether (20, Table 6) did not affect affinity in our binding
assay, moreover this compound showed no activity in the functional assay highlighting the importance of the
secondary amine contained within 1 and the potential requirement of a hydrogen-bond donor-acceptor at the
4-position for cooperativity with dopamine.
Table 6. Functional Parameters for Analogues of 1 with Chemical Modifications to the 4-position & 5,6-
Fused System Derived from cAMP BRET Assay
aEstimate of the negative logarithm of the equilibrium dissociation constant determined in an cAMP functional assay.
bEstimate of the logarithm of the net cooperativity factor between the modulator and dopamine. cEstimate of the
logarithm of the modulatory effect upon efficacy factor induced by the allosteric modulator. nd = inactive at
concentrations up to 100 µM. Values represent the mean ± S.E.M. from at least three independent experiments
performed in duplicate.
Our binding experiments revealed that modifications at the 2-position of the thienopyrimidine can
influence the degree of negative cooperativity between the modulator and [3H]raclopride. Therefore, we
examined the functional impact of removing the morpholinomethyl moiety with respect to varying substituents
at the 4-position. Maintaining the m-(trifluoromethyl)anilino substituent (23a) did not affect functional affinity
but resulted in a 3-fold increase in the modulatory effect upon dopamine efficacy (β = 0.10, Table 7). The
R1 R2 R3
apKB
(KB, µM)
bLog α
(α)
cLog β
(β)
15 H N(CH3)2 5.31 ± 0.15 (4.90) -0.17 ± 0.14 (0.68) -0.84 ± 0.10 (0.15)
18 - NCH3 nd
19 - N(CH2CH3)2 6.18 ± 0.16 (0.662) -0.17 ± 0.17 (0.68) -1.10 ± 0.10 (0.08)
20 - nd
44 H H N(CH2CH3)2 5.50 ± 0.10 (3.13) -1.10 ± 0.16 (0.08) -0.62 ± 0.15 (0.24)
O CF3
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N,N-diethylamino substituent (23b) not only maintained functional affinity (KB = 1 µM), but gave rise to
almost complete attenuation of dopamine signalling at a concentration of 10 µM indiciative of a very high
negative modulatory effect upon dopamine efficacy (Figure 5C, Table 7). Interestingly, the pyrimidinone
analogue (21) was inactive and is in agreement with our finding that the secondary amine is a key structural
determinant of cooperativity.
We next focused on the non-functionalised methylene spacer group within 1, and the importance of
linker length (Table 7). Increasing linker length by one carbon atom had no effect on affinity, however the
nature of allostery was altered as 39a modulated dopamine affinity with little effect upon dopamine efficacy
(α = 0.23). Further extension of linker length by one carbon 39b engendered an additional modulatory effect
upon dopamine efficacy (KB = 1.39 µM, α = 0.21, β = 0.40). Moreover, further extension of the linker 39c was
observed to not only increase functional affinity (KB = 611 nM), but also increased negative cooperativity with
dopamine efficacy (β = 0.03). The addition of the N,N-diethylamino substituent (40) resulted in a similar
affinity as determined for 39c, but displayed pharmacology best fit with a competitive model (Table 7).
Interestingly, isosteric replacement of the morpholino nitrogen with a methine group (33a) caused a
10-fold increase in functional affinity (KB = 622 nM), as well as enhancing the negative allosteric modulatory
effect upon dopamine efficacy (β = 0.13). This finding suggests that the ionizable nitrogen within 1 is not a
structural requirement to maintain modulatory activity at the D2R. However, the N-N-diethylamino
substitution (33b) was not tolerated in conjunction with the tetrahydropyran as the compound was inactive in
this functional assay. Isosteric replacement of the morpholino oxygen for a methylene group via the
incorporation of piperidine (26) maintained functional affinity (KB = 6.52 µM), but saw a reduction in negative
allosteric cooperativity (α = 0.49, β = 0.68) compared to 33a.
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Table 7. Functional Parameters for Analogues of 1 with Chemical Modifications to the 2-Position
Derived from cAMP BRET Assay
aEstimate of the negative logarithm of the equilibrium dissociation constant ± SEM determined in an cAMP functional
assay. bEstimate of the logarithm of the net cooperativity factor between the modulator and dopamine ± SEM determined
in an cAMP functional assay. nd = inactive at concentrations up to 100 µM. Values represent the mean ± S.E.M. from
at least three independent experiments performed in duplicate.
We also investigated the impact of bis-functionalisation of 1 with respect to incorporating various
amines at the 4-position of 1 in this functional assay (Table 8). Two analogues of 1 that incorporate the
morpholinobutyl substituent, in conjunction with removal of the fused cyclohexane system, together with one
of either m-CF3-anilino (43a) or N,N-diethylamino substituents (43b) maintained functional affinity (KB = 1.3
µM and 1.4 µM, respectively) comparable to 1, but now displayed a higher level of negative cooperativity
R1 R2
apKB
(KB, µM)
bLog α 
(α)
cLog β 
(β)
21 H C=O nd
23a H 4.60 ± 0.17 (25.4) = 0 -1.02 ± 0.35 (0.10)
23b H N(CH2CH3)2 5.72 ± 0.13 (1.92) = 0 = -3.0
26 -5.16 ± 0.13 (6.98) -0.46 ± 0.12 (0.34) -0.22 ± 0.08 (0.60)
33a 6.22 ± 0.26 (0.622) -0.89 ± 0.29 (0.13) -0.63 ± 0.19 (0.23)
33b N(CH2CH3)2 nd
39a 6.01 ± 0.17 (0.981) -0.63 ± 0.05 (0.23) = 0
39b 5.79 ± 0.11 (1.63) -0.68 ± 0.12 (0.21) -0.40 ± 0.08 (0.40)
39c 6.21 ± 0.11 (0.611) -0.72 ± 0.18 (0.19) -1.50 ± 0.15 (0.03)
40 N(CH2CH3)2 5.80 ± 0.20 (1.77) e Schild Slope: 1.07 ± 0.11
HN CF3
O
HN CF3
O
N HN CF3
O
N
O
N
2
HN CF3
O
N
3
HN CF3
O
N
4
HN CF3
O
N
4
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with both dopamine affinity and efficacy (Table 8). These data further indicate that linker length extension of
the morpholine moiety acts to increase negative cooperativity with dopamine.
Table 8. Functional Parameters for Analogues of 1 with Bi-Functionalisation in Conjunction with
Aromatic or Aliphatic 4-Substituted Amine
aEstimate of the negative logarithm of the equilibrium dissociation constant determined in an cAMP functional assay.
bEstimate of the logarithm of the net cooperativity factor between the modulator and dopamine. cEstimate of the
logarithm of the modulatory effect upon efficacy factor induced by the allosteric modulator. Values represent the mean
± S.E.M. from at least three independent experiments performed in duplicate.
In agreement with our binding data, analogues of 1 devoid of both the morpholinomethyl and fused
cyclohexane moieties but incorporating one of either m-(trifluoromethyl)aniline (47a), or N,N-diethylamine
(47b, Figure 5D) maintained functional affinity and displayed robust negative cooperativity with dopamine
efficacy and affinity despite the lack of a substituent at the 2-position or the presence of the fused cyclohexane
system (KB = 1.3 µM, α = 0.05, β = 0.15 and KB = 1.4 μM, α = 0.13, β = 0.06, respectively, table 8). These
data demonstrate the utility of the thieno[2,3-d]pyrimidine scaffold as a NAM of the dopamine effect as
‘pruned back’ analogues maintain negative allosteric cooperativity whilst preserving functional affinity
relative to 1. Through successive compound iterations, both the lipophillic ligand efficiency (LLE) and ligand
efficiency (LE) of the scaffold have been enhanced significantly compared to that of 1, with the most efficient
R1 R2
apKB
(KB, µM)
bLog α
(α)
cLog β
(β)
43a 5.85 ± 0.10 (1.4) -0.88 ± 0.16 (0.13) -1.21 ± 0.16 (0.06)
43b N(CH2CH3)2 5.89 ± 0.09 (1.3) -1.34 ± 0.21 (0.05) -0.82 ± 0.18 (0.15)
47a H 6.13 ± 0.21 (0.8) -0.43 ± 0.06 (0.37) = 0
47b H N(CH2CH3)2 5.31 ± 0.07 (4.6) = 0 -0.89 ± 0.04 (0.13)
O
N
4
HN CF3
O
N
4
HN CF3
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compound being 47b (Figure 6, LLE = 2.48, LE = 0.54). This reveals the versatility of the scaffold for further
structural optimisation and development of ligands that non-competitively modulate dopamine affinity and
signalling efficacy at the D2R. Collectively, these results demonstrate that analogues of 1 mediate their effects
through an allosteric mode of action. While we were able to gain only relatively modest (10-fold) improvement
in affinity, our SAR study revealed compounds with a range of modulatory effects upon dopamine efficacy
and/or affinity.
Figure 6. Lipophillic ligand efficiencies (LLE), and ligand efficiencies (LE) of 1, 19, 23b, and 47b calculated
according to equilibrium dissociation constants derived from functional interaction experiments measuring
cAMP accumulation. Multiple compound iterations have yielded improvements in the scaffold’s efficiency
through decreased molecular weight and functional binding affinity. This is particularly evident with
compound 47b as it shows a marked improvement in both LLE and LE compared to that of 1, resulting in a
promising fragment-like starting scaffold that can be elaborated through multiple vectors.
Molecular Docking Studies. The recently solved structure of D2R receptor (PDB ID: 6C38)32 provides an
opportunity to accurately model the allosteric binding of compound 1 and a library of structurally diverse
analogues. Specifically, we were interested in the interactions of these allosteric compounds with the
orthosteric ligand, as reflected in the [3H]raclopride equilibrium binding assays (Table 1). While the D2R
structure was solved with the atypical antipsychotic drug risperidone, we first generated a conformational
model of raclopride bound to the D2R (D2RRaclo). Flexible docking of raclopride shows a pose similar to the
pose of eticlopride found in the D3R structure. Both raclopride and eticlopride are known to bind to the
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orthosteric pocket of the D2R commonly occupied by dopamine, however, since it is bulkier than dopamine,
the allosteric pocket in the D2RRaclo complex is shallower, as compared to the D2RDopa complex.
Docking of compound 1 in the D2RRaclo complex consistently yielded the best scoring pose shown in Figure
7. This pose is stabilised by a hydrogen bond between the ionised morpholine secondary amine and the oxygen
atom of the side-chain of S4097.36 (Ballesteros-Wenstein nomenclature33), as well π-π stacking interactions of 
the thienopyrimidine moiety with Y4087.35 and W100ECL1 side chains. In addition, the fused cyclohexane ring
system is positioned in the hydrophobic sub-pocket located between helices V and VI formed by the residues
I184ECL2, V1905.39, H3946.55, whereas the phenyl ring bearing the m-CF3 substituent is placed between
helices VI and VII, and ECL3, and is lined by the residues N3966.58, N402ECL3, P4057.32, and Y4087.35 (Figure
7).
Figure 7. Compound 1 (orange carbon atoms) predicted binding mode in complex with raclopride (magenta
carbon atoms) (D2RRaclo conformational model (PDB ID: 6C38)). D2R structural model is shown in light grey
cartoon and stick presentation.
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The key SAR data support the consistent binding pose of compound 1 and its analogues as illustrated in Figure
8 and Supplementary Figure 2. First, we examined modifications to the fused cyclohexane system of 1, (14a-
j). Most analogues bind in a similar mode, maintaining the key interactions of the scaffold (Supplementary
Figure 2A). At the same time, the docking illustrates a modest binding dependence on the size of this fused
hydrophobic ring, as replacement of the cyclohexane with either cyclopentane (14a) or cycloheptane (14b)
would make less favorable hydrophobic interactions, reducing allosteric binding affinity by ~2-4-fold (Figure
8A). Moreover, compounds that lack the fused ring system (14h, j) showed an even more pronounced decrease
in binding, consistent with loss of interactions with this hydrophobic sub-pocket (Figure 8B).
Next, we examined compounds with variations to in the m-CF3 substituent (16a-c, 17) positioned between
helices VI and VII, and ECL3, but exposed to solvent. As the CF3 substituent is favorable for solvent
interactions, its removal in 16a explains the observed 6-fold decrease in binding for this compound. The
reduction is much smaller for derivatives that have polar substituents in this position, 3-OH (17) and 3-OMe
(16c) (Supplementary Figure 2B).
Next, we examined compounds with variations in N-(3-trifluoromethyl)phenylamino substituent (15, 18, 19).
The docking poses place N,N-dimethylamino (15), N-methylamino (18), and N,N-diethylamino moieties (19)
into the hydrophobic sub-pocket in the proximity of Y4087.35 and W100ECL1, with 19 having the most
extensive hydrophobic contacts. This is in agreement with an improved binding affinity for 19 (Supplementary
Figure 2C). The secondary amine of compound 1 is not engaged in any interactions, and its isosteric
replacement to an ether (20) did not impact the predicted binding mode (Supplementary Figure 2D), nor its
binding affinity (Table 1).
Interestingly, removal of the morpholinomethyl moiety (23a) maintained the π-π stacking interactions of the 
thienopyrimidine moiety with the Y4087.35 and W100ECL1, though slightly shifting the scaffold, enabling an
additional hydrogen bond interaction with T4127.39. We hypothesize that though loss of the morpholine system
abolished the interaction with the S4097.36 (Figure 8C), the new hydrogen bond at least partially compensated
the loss, maintaining binding affinity of this analogue (Table 1). However, replacing morpholine with
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piperidine (26) leads to 2.5-fold decrease in affinity, reflecting replacement of a polar oxygen with a carbon
in this solvent-exposed position (Supplementary Figure 2E).
Moreover, removal of the tertiary amine in the morpholine ring abolishes the hydrogen bond interaction of
33a with S4097.36 (Figure 8D), with the importance of this hydrogen bond corroborated by a ~7-fold decrease
in affinity for this compound (Table 1).
Furthermore, we evaluated the effect of elongating the methylene linker to the morpholine substituent (39a-
c). In our model, increasing the linker length did not hinder the ability of the compounds to maintain crucial
interactions, and even helped to improve complementarity of 39c with the binding pocket, in accordance with
its improved affinity (Figure 8E).
Other docked analogues, characterised by morpholinomethyl deletion (23b), tetrahydropyranomethyl (33b),
morpholinobutyl (40), and fused cyclohexane deletion (44), also maintained the crucial π−π interactions with
Y4087.35 and W100ECL1 (Supplementary Figure 2F). Similar poses were obtained for the two compounds 43a-
b, comprised of the morpholinobutyl moiety and four carbon linker, but devoid of the fused cyclohexane
system (Supplementary Figure 2G).
Finally, we docked compounds devoid of the fused cyclohexane system and morpholinomethyl moieties but
maintained substitution with one of either m-trifluoromethylanilino or N,N-diethylamino (47a-b). This
dramatically reduced the size of the scaffold, but also maintained π−π stacking interactions with Y4087.35 and
W100ECL1, while shifting to gain a hydrogen bond interaction with T4127.39 (Figure 8F), which is in agreement
with only a minor loss of binding affinity (Table 1).
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Figure 8. Compound 1 analogues in complex with D2RRaclo (PDB ID: 6C38). Compounds with variation in
the fused cyclohexane system: (A) Compounds 14a, c. (B) Compounds 14h, j. (C) Compound devoid of
morpholinomethyl moiety (23a). (D) Compound with tetrahydropyran moiety (33a). (E) Compounds with
variations in alkyl linker length to the morpholine motif (39c). (F) Fragment-like compounds (47a-b).
 CONCLUSIONS
In this study, we report the pharmacological validation of a VLS hit, confirming it exerts its effect via an
allosteric mode of action at the D2R, as predicted by our initial modeling studies. We subsequently describe
the design and characterisation of a structurally novel series of dopamine D2R NAMs based on this thieno[2,3-
d]pyrimidine scaffold, demonstrating its scope for future development of D2R NAMs. The impact of structural
modification was assessed with respect to thienopyrimidine substituents (2-, 4-, 5- and 6-positions), isosteric
replacement of the aniline nitrogen with respect to hydrogen-bonding, as well as the importance of bearing an
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ionisable nitrogen at differing linker lengths on the 2-substituent and its subsequent impact on the allosteric
pharmacology of 1. The majority of active compounds displayed comparable binding affinities to that of 1.
Rather, the structural modifications within this study had a profound effect upon the extent of modulation of
dopamine binding and/or efficacy. Indeed, while 1 exerted its effect predominaly via negative modulation of
dopamine efficacy, we identified analogues of 1 that displayed modulatory effects upon dopamine affinity
(e.g. 14a, 14i, 39a), and those that displayed modulatory effects upon both dopamine affinity and efficacy
(e.g. 17, 19, 43a). Maintaining a hydrogen-bond donor (secondary amine) at the 4-position was found to be a
requirement for cooperativity with dopamine, as thienopyrimidinone analogues were inactive in our functional
assay. Moreover, the ether analogue of 1 (20) was also inactive in our functional assay, suggesting this
modification is not well tolerated. Most significantly, we show that this scaffold can be effectively ‘pruned
back’ of morpholinomethyl and fused cyclohexane moieties, to reveal a low molecular weight fragment-like
core with low µM functional affinity and very high lipophilic ligand efficiency (47a-b). Our molecular
docking studies, using the recently determined crystal structure as a template, provide some insight into the
molecular determinants of this SAR. Thus, this minimal thieno[2,3-d]pyrimidine scaffold provides an
attractive starting point for further structural interrogation and elaboration of the core scaffold to achieve high
affinity, low molecular weight NAMs of the D2R with varying effects upon dopamine binding and/or function.
 EXPERIMENTAL SECTION:
Chemistry: General Information and Synthetic Procedures. Chemicals and solvents were purchased
from standard suppliers and used without further purification. Davisil silica gel (40−63 μm) for flash column
chromatography was supplied by Grace Davison Discovery Sciences (Victoria, Australia), and deuterated
solvents were purchased from Cambridge Isotope Laboratories, Inc. (USA, distributed by Novachem PTY.
Ltd., Victoria, Australia). Reactions were monitored by thin layer chromatography on commercially available
precoated aluminum-backed plates (Merck Kieselgel 60 F254). Visualisation was by examination under UV
light (254 and 366 nm). A solution of ninhydrin (in ethanol) was used to visualise primary and secondary
amines. All organic extracts collected after aqueous workup procedures were dried over anhydrous MgSO4 or
Na2SO4 before gravity/vacuum filtering and evaporation to dryness. Organic solvents were evaporated in
Page 40 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
41
vacuo at ≤40 °C (water bath temperature). 1H NMR and 13C NMR spectra were recorded on a Bruker Avance
Nanobay III 400 MHz Ultrashield Plus spectrometer at 400.13 and 100.62 MHz, respectively. Chemical shifts
(δ) are recorded in parts per million (ppm) with reference to the chemical shift of the deuterated solvent. 
Coupling constants (J) are recorded in Hz, and the significant multiplicities described by singlet (s), doublet
(d), triplet (t), quadruplet (q), broad (br), multiplet (m), doublet of doublets (dd), and doublet of triplets (dt).
Spectra were assigned using appropriate COSY, distortionless enhanced polarization transfer (DEPT), HSQC,
and HMBC sequences. LC-MS were run to verify reaction outcome and purity using an Agilent 6120 series
single quad coupled to an Agilent 1260 series HPLC. The following buffers were used: buffer A, 0.1% formic
acid in; buffer B, 0.1% formic acid in MeCN. The following gradient was used with a Poroshell 120 EC-C18
50 mm × 3.0 mm 2.7 μm column, and a flow rate of 0.5 mL/min and total run time of 5 min; 0−1 min 95% 
buffer A and 5% buffer B, from 1 to 2.5 min up to 0% buffer A and 100% buffer B, held at this composition
until 3.8 min, 3.8−4 min 95% buffer A and 5% buffer B, held until 5 min at this composition. Mass spectra 
were acquired in positive and negative ion mode with a scan range of 100−1000 m/z. UV detection was carried
out at 214 and 254 nm. All retention times (tR) are quoted in minutes. All screening compounds were of >95%
purity unless specified in the individual monologue. All NMR experiments were performed in CDCl3 to permit
comparison of the spectra of the various analogues. Experiments were performed in acetone-d6, DMSO-d6, or
MeOH-d4 if selected analogues lacked solubility in CDCl3.
General Synthetic Procedures. General Procedure A for the Gewald Synthesis of 2-Amino-3-Carbethoxy
Thiophenes 5, 10a-c. To a stirred solution of ethyl cyanoacetate (1 equiv.) in absolute ethanol was added sulfur
powder (1 equiv.), followed by the aldehyde or ketone (1 equiv) at r.t. under N2 and the resulting mixture
cooled to 0-5 °C. To this was added diethylamine (1 equiv.) and the reaction mixture warmed to r.t. and
subsequently stirred at 50-55 °C for 5 h. The reaction was concentrated under reduced pressure and the residue
was chromatographed on silica eluting with petroleum ether/EtOAc (10:1) to give the desired compound as a
solid or oil which can be recrystallised from an appropriate solvent as indicated.
General Synthetic Procedures. General Procedure B for the Gewald Synthesis of 2-Amino-3-Carbethoxy
Thiophenes 5, 10d-i. An equimolar mixture of powdered sulfur and morpholine was stirred until total
dissolution of the sulfur. After, the ethyl cyanoacetate (1 equiv.) and the aldehyde or ketone (1 equiv.) were
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added to the reactional mixture, which was stirred at room temperature for ~18 h. After completion of the
reaction, as monitored by TLC, the crude product was chromatographed on silica with an appropriate eluent
as indictaed to afford the desired compound which could be recrystallised from an appropriate solvent as
indicated.
General Procedure C for the Preparation of 6, 11a-j, 31, 36a-c, 37b-c, 41. The required amino ethyl ester
thiophene (1 equiv) and appropariate nitrile (1.2 equiv) were taken up in 1,4-dioxane, heated to 50 °C, and
passed with dry HCl gas (Kipp´s apparatus) until the starting material was absent in 3-24 h or a precipitate
formed. The reaction mixture was filtered directly and the solid washed with n-hexane to obtain the desired
compound. Depending on purity, the solid may be recrystallised from an appropriate solvent or reacted without
further purification. Alternatively, the reaction mixture can be concentrated under reduced pressure and the
residue chromatographed with an appropriate eluent as indicated.
General Procedure D for the Preparation of 7, 12a-j, 37a. The required 2-chloro-thienopyrimidinone (1
equiv.) was taken up in DMF. To this solution/suspension was added morpholine (2.5 equiv) and the resulting
solution/suspension was stirred at 100 °C for 2-3 h. The reaction mixture was then cooled to room temperature
or ~4 °C to induce crystallisation of product. Any crystals were collected using vacuum filtration, washed
with cold i-PrOH and again recrystallised from i-PrOH. In the case of present morpholinium hydrochloride,
the solids were dissolved in CHCl3, washed with 5% NaHCO3 solution, water, brine, and the organic extracts
concentrated in vacuo. If no crystallisation from reaction mixture was evident, the residue can be
chromatographed on silica using 1% Et3N/EtOAc unless otherwise indicated.
General Procedure E for the Preparation of Chloropyrimidines 8, 13a-j, 22, 25, 38a-c, 42, 46. The required
thienopyrimidinone (1 equiv.) was taken up in toluene. To this solution/suspension was added phosphorous
oxychloride (4 equiv), N,N-dimethylformamide (cat.) and the solution/suspension was stirred at 100 °C. After
TLC has indicated complete consumption of starting material, the reaction mixture was slowly introduced into
a stirred suspension of ice water and the pH adjusted to ~12 with 6 M NaOH. The aqueous phase was extracted
with EtOAc and the combined organic extracts dried over anhydrous sodium sulfate and concented in vacuo.
The resulting oil/solid, depending on purity, can be reacted without further purification, or further purified
using column chromatography (1:99 Et3N:EtOAc) or recrystallised as indicated.
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General Procedure F for the Synthesis of 1, 14a-j, 16a-c, 18-20, 23a-b, 33a-b, 39a-c, 40, 43a-b, 44, 47a-b.
In a suitable microwave reaction vessel the required chloropyrimidine (1equiv.) was taken up in i-PrOH. To
this was added the required amine (1.1 equiv) and the mixture irradiated under stirring at 120 ˚C for 1-2 h. 
Upon completion of the reaction, the mixture can purified using silica gel chromatography to afford the
compound. Similarly, any precipitate can be collected under vacuum and washed with cold i-PrOH to afford
the desired compound.
2-(Morpholinomethyl)-N-(3-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-4-amine (1). General procedure F. The residue was chromatographed on silica (1:99
MeOH/CHCl3) which furnished the title compound as a white foam (160 mg, 70%). LCMS (m/z): 449.2 [M
+ H]+. HPLC: tR 7.912 min. HRMS (m/z): C23H23F3N3OS requires 449.1671 [M + H]+; found 449.1661. 1H
NMR  δ 8.17 (s, 1H), 7.93 (dd, J = 8.1, 1.6 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.34 – 7.31 (d, J = 7.7 Hz, 1H),
7.26 (s, 1H), 3.77 (s, 2H), 3.09 (t, J = 6.0 Hz, 2H), 2.87 (t, J = 6.0 Hz, 2H), 2.58 (s, 4H), 2.04 – 1.97 (m), 1.98
– 1.94 (m, 2H), 1.66 (dt, J = 11.2, 5.6 Hz, 4H). 13C NMR (CDCl3)  δ 167.5, 161.4, 154.2, 139.7, 135.0, 131.4 
(q, J = 32.3 Hz), 129.5, 124.2, 124.1 (q, J = 272.4 Hz), 123.2, 119.7 (q, J = 3.8 Hz), 117.1 (q, J = 4.0 Hz),
115.1, 65.8, 54.8, 26.6, 26.0, 24.3, 22.7, 22.5.
2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate33 (4). General Procedure A. The reaction
mixture was kept for 30 min at 0 °C and formed crystals were collected under vacuum filtration, washed with
chilled ethanol (2 × 50 mL) and dried to give the title compound as bright yellow needles which were used as
such for the next reaction without further purification (2.83 g, 80%). mp: 110-114 ˚C. 1H NMR (d6-acetone)
δ 6.88 (s, 2H), 4.21 (q, J = 7.1 Hz, 2H), 2.72 – 2.60 (m, 2H), 2.45 (m, 2H), 1.81 – 1.63 (m, 4H), 1.29 (t, J =
7.1 Hz, 3H). 13C NMR (d6-acetone) δ 165.6, 162.9, 131.9, 116.2, 104.1, 58.7, 26.8, 24.1, 23.1, 22.7, 13.9. 
LCMS (m/z): 226.2 [M + H]+. HPLC: tR 8.389 min. HRMS (m/z): C11H15NO2S requires 225.0818 [M + H]+;
found 225.0818.
2-(Chloromethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (6).16 General
procedure C. The reaction mixture was filtered directly and the solid washed with n-hexane to obtain the
desired compound as a beige solid (4.21 g, 93%). LCMS (m/z): 255.1 [M + H]+. HPLC: tR 6.858 min. HRMS
(m/z): C11H11ClN2OS requires 255.0354 [M + H]+; found 255.0353. 1H NMR (d6-DMSO) δ 12.72 (s, 1H), 
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4.56 (s, 2H), 2.85 (t, J = 5.8 Hz, 2H), 2.73 (t, J = 5.8 Hz, 2H), 1.76 (ddd, J = 7.5, 6.8, 4.4 Hz, 4H). 13C NMR
(d6-DMSO) δ 162.4, 158.6, 152.4, 133.7, 131.3, 122.1, 43.0, 25.6, 24.9, 22.8, 22.1.  
2-(Morpholinomethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (7). General
procedure D. Reaction cooled and crystals collected under vacuum filtration to obtain the desired compound
as a white crystalline solid (2.59 g, 70%). LCMS (m/z): 306.1 [M + H]+. HPLC: tR 4.334 min. 1H NMR
(CDCl3) δ 10.14 (s, 1H), 3.80 – 3.73 (m, 4H), 3.57 (s, 2H), 3.09 – 3.02 (m, 2H), 2.94 (t, J = 7.3 Hz, 2H), 2.63
– 2.57 (m, 4H), 2.51 – 2.40 (m, 2H). 13C NMR (CDCl3) δ 168.6, 158.2, 152.2, 140.1, 138.7, 119.5, 66.7, 60.6, 
53.6, 32.2, 29.5, 28.9, 27.
4-((4-Chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)methyl)morpholine (8).
General Procedure E. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the compound
as a brown oil (270 mg, 67%). LCMS (m/z): 324.1 [M + H]+. HPLC: tR 5.112 min. 1H NMR (CDCl3) δ 3.80 
(s, 2H), 3.06 (t, J = 4.2 Hz, 2H), 2.84 (t, J = 4.2 Hz, 2H), 2.52 – 2.49 (m, 4H), 1.93 – 1.86 (m, 2H), 1.67 – 1.57
(m, 4H), 1.49 – 1.36 (m, 2H). 13C NMR (CDCl3) δ 169.4, 161.4, 152.9, 138.9, 126.9, 126.9, 65.2, 54.7, 26.3, 
26.0, 25.7, 24.1, 22.2.
Ethyl 2-amino-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate (10a).15 General Procedure A. The
reaction was concentrated under reduced pressure and the residue eluted through a silica gel column (10:1
petroleum ether:EtOAc) to afford the compound as a yellow solid which later turned a dark brown (1.18 g,
37%). General procedure B. The reaction was concentrated under reduced pressure and the residue eluted
through a silica gel column (10:1 petroleum ether/EtOAc) to afford the compound as a yellow solid which
later turned brown (2.21 g, 44%). LCMS (m/z): 212.1 [M + H]+. HPLC: tR 8.102 min. 1H NMR (CDCl3) δ 
5.85 (s, 2H), 4.24 (q, J = 7.1 Hz, 2H), 2.82 (ddd, J = 7.9, 3.9, 1.9 Hz, 2H), 2.74 – 2.68 (m, 2H), 2.35 – 2.26
(m, 2H), 1.32 (t, J = 7.1 Hz, 1H). 13C NMR (CDCl3) δ 166.4, 165.9, 142.8, 121.4, 103.0, 59.5, 30.9, 29.0, 
27.4, 14.6.
Ethyl 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate (10b). General procedure A.
The reaction was concentrated under reduced pressure and the residue chromatographed on silica (10:1
petroleum ether:EtOAc). The resulting residue was recrystallised from CHCl3/petroleum ether to afford the
desired compound as yellow crystals (1.55 g, 48%). LCMS (m/z): 240.2 [M + H]+. HPLC: tR 8.791 min.
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General procedure B. The crude product was purified by silica gel column chromatography (10:1 petroleum
ether:EtOAc) to afford the title compound as a yellow solid (3.87 g, 72%). 1H NMR (CDCl3 δ 5.76 (s, 2H), 
4.28 (q, J = 7.1 Hz, 2H), 3.00 – 2.94 (m, 2H), 2.60 – 2.54 (m, 2H), 1.85 – 1.76 (m, 2H), 1.68 – 1.56 (m, 4H),
1.34 (t, J = 7.1 Hz, 3H). 13C NMR (CDCl3) δ 166.1, 159.9, 138.0, 121.4, 107.6, 59.6, 32.2, 28.7, 28.7, 27.9, 
27.0, 14.5.
Ethyl 2-amino-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxylate (10c). General procedure A.
The solvent was removed under reduced pressure and the residue eluted through a silica gel column (10:1
petroleum ether/EtOAc). The product was recrystallised from CHCl3/petroleum ether to give the desired
compound as yellow crystals (1.32 g, 37%). LCMS (m/z): 254.2 [M + H]+. HPLC: tR 9.405 min. General
procedure B. After completion of the reaction (24 h), as monitored by TLC, the mixture was concentrated
under reduced pressure and the crude product was purified by silica gel column chromatography (10:1
petroleum ether:EtOAc) to afford the title compound as a yellow solid (2.63 g, 65%). 1H NMR (CDCl3) δ 5.94 
(s, 1H), 4.27 (q, J = 7.1 Hz, 2H), 2.85 – 2.77 (m, 2H), 2.61 – 2.57 (m, 2H), 2.43 – 2.36 (m, 1H), 1.91 – 1.82
(m, 1H), 1.65 – 1.59 (m, 2H), 1.58 – 1.52 (m, 2H), 1.49 – 1.41 (m, 2H), 1.37 – 1.26 (m, 3H). 13C NMR (CDCl3)
δ 166.1, 161.5, 134.9, 120.2, 106.2, 59.5, 32.1, 29.9, 26.8, 26.6, 25.9, 25.7, 14.4.
Ethyl 2-amino-5-phenylthiophene-3-carboxylate (10d). General procedure B. After completion of the
reaction, as monitored by TLC, the mixture was concentrated under reduced pressure and the crude product
was purified by silica gel column chromatography (10:1 petroleum ether:EtOAc). This resulting brown solid
was recrystallised from i-PrOH to afford the title compound as dark orange needles (6.30 g, 54%). LCMS
(m/z): 248.1 [M + H]+. HPLC: tR 7.946 min. 1H NMR (CDCl3) δ 7.47 – 7.42 (m, 2H), 7.36 – 7.30 (m, 2H), 
7.25 (s, 1H), 7.23 – 7.18 (m, 1H), 6.02 (s, 2H) 4.31 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H). 13C NMR
(CDCl3) δ 165.5, 162.1, 134.1, 128.9, 126.7, 124.9, 124.8, 121.3, 108.1, 60.0, 14.6.
Ethyl 2-amino-4-phenylthiophene-3-carboxylate (10e). General procedure B. The reaction mixture was
concentrated under reduced pressure and the crude product was purified by silica gel column chromatography
(10:1 petroleum ether:EtOAc). This resulting yellow solid was recrystallised from i-PrOH to afford the title
compound as yellow crystals (4.88 g, 49%). LCMS (m/z): 248.1 [M + H]+. HPLC: tR 7.379 min. 1H NMR
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(CDCl3) δ 7.33 – 7.28 (m, 5H), 6.10 (s, 2H), 6.07 (s, 2H), 4.04 (q, J = 7.1 Hz, 2H), 0.93 (t, J = 7.1 Hz, 3H).
13C NMR (CDCl3 δ 165.8, 163.9, 141.7, 138.6, 129.0, 127.3, 126.9, 105.6, 59.5, 13.7.
Ethyl 2-amino-5-benzylthiophene-3-carboxylate (10f). General procedure B. After completion of the
reaction, as monitored by TLC, the mixture was concentrated under reduced pressure and the crude product
chromatographed on silica (10:1 petroleum ether:EtOAc) to afford the title compound as a yellow oil (2.71 g,
35%). LCMS (m/z): 262.1 [M + H]+. HPLC: tR 8.633 min. 1H NMR (CDCl3 δ 7.30 – 7.26 (m, 2H), 7.23 – 7.18 
(m, 3H), 6.69 (t, J = 1.0 Hz, 1H), 5.83 (s, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.87 (s, 2H), 1.30 (t, J = 7.1 Hz, 1H).
13C NMR (CDCl3) δ 165.4, 162.3, 139.9, 128.5, 128.49, 126.5, 125.1, 122.8, 106.1, 59.6, 36.0, 14.5.
Ethyl 2-amino-4-cyclohexylthiophene-3-carboxylate (10g). General procedure B. After completion of the
reaction, as monitored by TLC, the reaction mixture was concentrated under reduced pressure and the crude
product purified by silica gel column chromatography (10:1 petroleum ether:EtOAc). Collected fractions were
concentrated under reduced pressure and placed in the freezer for 2 h. Formed solids were collected under
vacuum and washed with petroleum ether to afford the compound as clear crystals (3.56 g, 38%). LCMS (m/z):
254.2 [M + H]+. HPLC: tR 8.936 min. 1H NMR (CDCl3) δ 6.06 (s, 2H), 5.85 (s, 1H), 4.29 (q, J = 7.1 Hz, 2H),
3.03 (tt, J = 11.4, 2.5 Hz, 1H), 1.97 (d, J = 12.0 Hz, 2H), 1.80 (d, J = 12.6 Hz, 2H), 1.73 (d, J = 12.5 Hz, 1H),
1.37 (t, J = 7.2 Hz, 5H), 1.28 – 1.15 (m, 3H). 13C NMR (CDCl3) δ 166.2, 164.5, 147.4, 100.6, 59.7, 39.4, 34.1, 
27.1, 26.6, 14.1.
Ethyl 2-amino-4,5-dimethylthiophene-3-carboxylate (10h). General procedure B. After completion of the
reaction, as monitored by TLC, the mixture was concentrated under reduced pressure and the crude product
was purified by silica gel column chromatography (10:1 petroleum ether:EtOAc) to afford the title compound
as a pale yellow solid which was recrystallised from i-PrOH (3.41 g, 38%). LCMS (m/z): 200.1 [M + H]+.
HPLC: tR 7.265 min. 1H NMR (CDCl3) δ 5.90 (s, 2H), 4.27 (q, J = 7.1 Hz, 2H), 2.16 (d, J = 0.7 Hz, 3H), 2.15
(d, J = 0.7 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR (CDCl3) δ 166.2, 161.0, 130.4, 113.9, 107.0, 59.7, 14.9, 
14.5, 12.4.
Ethyl 2-amino-5-cyclohexylthiophene-3-carboxylate (10i). General procedure B. After completion of the
reaction, as monitored by TLC, the mixture was concentrated under reduced pressure and the crude product
was chromatographed on silica (10:1 petroleum ether:EtOAc) to afford the title compound as a gold oil (3.05
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g, 73%). LCMS (m/z): 254.2 [M + H]+. HPLC: tR 8.918 min. 1H NMR (CDCl3) δ 6.62 (d, J = 1.1 Hz, 1H),
5.79 (s, 2H), 4.25 (q, J = 7.1 Hz, 2H), 2.57 – 2.48 (m, 1H), 2.00 – 1.91 (m, 2H), 1.82 – 1.76 (m, 2H), 1.72 –
1.65 (m, 1H), 1.36 – 1.29 (m, 7H), 1.23 – 1.13 (m, 1H). 13C NMR (CDCl3) δ 165.6, 160.9, 133.3, 119.1, 106.2, 
59.6, 39.0, 34.9, 26.4, 26.0, 14.6.
Ethyl 2-aminothiophene-3-carboxylate (10j).34 Triethylamine (7.34 mL, 52.6 mmol) was added dropwise
over 10 min to a mixture of 2,5-dihydroxy-1,4-dithiane (8.09 g, 52.6 mmol), ethyl cyanoacetate (11.2 mL, 105
mmol), and dimethylformamide (40 mL). The mixture was stirred for at 45 °C for 30 min, diluted with 0.4 M
acetic acid and extracted with ether. The ethereal layer was dried over sodium sulphate. The residue was eluted
through a silica gel column (10:1 petroleum ether:EtOAc) and the resulting fractions collected, concentrated
under reduced pressure and cooled at 4 °C to afford the compound as a light yellow crystalline solid (5.00 g,
55%). LCMS (m/z): 172.1 [M + H]+. HPLC: tR 6.123 min. 1H NMR (CDCl3) δ 6.98 (d, J = 5.8 Hz, 1H), 6.18
(d, J = 5.8 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR (CDCl3) δ 165.5, 162.7, 126.6, 
107.2, 106.9, 59.8, 14.6.
2-(Chloromethyl)-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one (11a). General
procedure C. The precipitate was collected and washed with cold 1,4-dioxane to afford the compound as a
beige solid (2.56 g, 70%.) LCMS (m/z): 292.1 [M + H]+. HPLC: tR 4.216 min. 1H NMR (d6-DMSO) δ 12.72 
(s, 1H), 4.54 (s, 2H), 2.97 – 2.85 (m, 4H), 2.37 (p, J = 7.2 Hz, 2H). 13C NMR (d6-DMSO) δ 167.2, 157.9, 
151.7, 139.7, 138.7, 119.3, 42.7, 29.1, 28.6, 27.5.
2-(Chloromethyl)-3,5,6,7,8,9-hexahydro-4H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one (11b).
General procedure C. The precipitate was collected and washed with cold 1,4-dioxane to afford the compound
as a white powder (5.00 g, 86%). LCMS (m/z): 269.1 [M + H]+. HPLC: tR 7.039 min. 1H NMR (d6-DMSO) δ 
12.71 (s, 1H), 4.57 (s, 2H), 3.31 – 3.21 (m, 2H), 2.86 – 2.79 (m, 2H), 1.90 – 1.78 (m, 2H), 1.69 – 1.49 (m,
4H). 13C NMR (d6-DMSO) δ 160.4, 158.7, 151.7, 137.6, 136.6, 122.2, 42.6, 32.0, 29.1, 27.3, 27.1, 26.9.
2-(Chloromethyl)-5,6,7,8,9,10-hexahydrocycloocta[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (11c).
General procedure C. The precipitate was collected and washed with cold 1,4-dioxane to afford the compound
as a white powder (3.01 g, 78%). LCMS (m/z): 283.0 [M + H]+. HPLC: tR 7.426 min. 1H NMR (d6-DMSO)
δ 12.68 (s, 1H), 4.55 (s, 2H), 3.06 – 2.99 (m, 2H), 2.90 – 2.82 (m, 2H), 1.59 (s, 4H), 1.41 – 1.36 (m, 2H), 1.29 
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– 1.19 (m, 2H). 13C NMR (d6-DMSO) δ 161.6, 158.2, 151.7, 136.1, 133.8, 121.6, 42.6, 31.5, 29.8, 26.1, 25.4, 
25.2, 24.3.
2-(Chloromethyl)-5-phenylthieno[2,3-d]pyrimidin-4(3H)-one (11d). General procedure C. The bright
orange suspension was filtered and the resulting solids were washed with cold 1,4-dioxane which afforded the
desired compound as a yellow solid (4.33 g, 82%). LCMS (m/z): 277.1 [M + H]+. HPLC: tR 6.476 min. 1H
NMR (d6-DMSO) δ 12.71 (s, 1H), 7.55 (s, 1H), 7.53 (dd, J = 7.9, 1.3 Hz, 2H), 7.41 – 7.37 (m, 2H), 7.35 (dd,
J = 6.6, 2.7 Hz, 1H). 13C NMR (d6-DMSO) δ 165.3, 157.8, 153.1, 138.5, 135.1, 129.4, 127.6, 127.5, 121.8, 
119.9, 42.5.
2-(Chloromethyl)-6-phenylthieno[2,3-d]pyrimidin-4(3H)-one (11e). General procedure C. The precipitate
was collected from the crude reaction mixture and washed with hot i-PrOH to afford the compound as a white
solid which was used without the need for further purification (4.57 g, 64%). LCMS (m/z): 277.1 [M + H]+.
HPLC: tR 6.752 min. 1H NMR (d6-DMSO) δ 12.72 (1H), 7.80 (s, 1H), 7.78 – 7.73 (m, 2H), 7.45 (dd, J = 8.1,
6.7 Hz, 2H), 7.38 – 7.34 (m, 1H), 4.62 (s, 2H).13C NMR (d6-DMSO) δ 162.9, 157.6, 153.2, 140.4, 132.6, 
129.3, 128.8, 125.8, 125.1, 117.3, 42.6.
6-Benzyl-2-(chloromethyl)thieno[2,3-d]pyrimidin-4(3H)-one (11f). General procedure C. The solvents
were removed under reduced pressure and the residue was chromatographed on silica (40% petroleum ether
in EtOAc). The collected fractions were concentrated under reduced pressure and the resulting solid was
recrystallised from CHCl3 affording the compound as white-yellow crystals (2.74 g, quantitative yield). LCMS
(m/z): 291.1 [M + H]+. HPLC: tR 6.680 min.1H NMR (d6-DMSO) δ 7.62 (s, 1H), 7.35 – 7.28 (m, 4H), 7.25 
(dd, J = 11.1, 4.3 Hz, 1H), 7.16 (s, 1H), 4.54 (s, 2H), 4.20 (s, 2H). 13C NMR (d6-DMSO) δ 163.1, 157.6, 152.5, 
142.9, 139.5, 128.7, 128.6, 123.7, 119.1, 42.7, 35.6.
2-(Chloromethyl)-5-cyclohexylthieno[2,3-d]pyrimidin-4(3H)-one (11g). General procedure C. The
precipitate was collected from the crude reaction mixture and washed with 1,4-dioxane. This afforded the
desired compound as a yellow solid which was used without the need for further purification (2.75 g, 70%).
LCMS (m/z): 283.1 [M + H]+. HPLC: tR 7.595 min. 1H NMR (d6-DMSO) δ 12.73 (s, 1H), 7.21 (s, 1H), 4.57 
(s, 2H), 3.26 (t, J = 9.6 Hz, 1H), 1.95 (d, J = 9.8 Hz, 2H), 1.77 (d, J = 11.6 Hz, 2H), 1.70 (d, J = 12.9 Hz, 1H),
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1.41 – 1.28 (m, 4H), 1.22 (dt, J = 24.7, 9.6 Hz, 1H). 13C NMR (d6-DMSO) δ 164.6, 158.3, 152.6, 144.8, 120.9, 
116.6, 42.5, 37.9, 33.1, 26.3, 25.8.
2-(Chloromethyl)-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one (11h). General procedure C. The
precipitate was collected from the crude reaction mixture, and washed with hot CHCl3 to afford the compound
as a yellow solid (3.38 g, 84%). LCMS (m/z): 229.0 [M + H]+. HPLC: tR 5.717 min. 1H NMR (d6-DMSO) δ 
12.69 (s, 1H), 4.55 (s, 2H), 2.36 (d, J = 0.8 Hz, 3H), 2.34 (d, J = 0.7 Hz, 1H). 13C NMR (d6-DMSO) δ 161.2, 
158.4, 151.9, 130.4, 128.8, 122.4, 42.6, 12.7, 12.7.
2-(Chloromethyl)-6-cyclohexylthieno[2,3-d]pyrimidin-4(3H)-one (11i). General procedure C. The
precipitate was collected from the crude reaction under vacuum filtration and washed with cold 1,4-dioxane.
The remaining filtrate was concentrated reduced under pressure and the resulting residue chromatographed on
silica (40:60 EtOAc:petroleum ether) to afford the compound as a yellow solid (2.56 g, 64%). LCMS (m/z):
283.0 [M + H]+. HPLC: tR 7.614 min. 1H NMR (d6-DMSO) δ 12.67 (s, 1H), 7.09 (d, J = 0.5 Hz, 1H), 4.57 (s,
2H), 2.89 – 2.78 (m, 1H), 1.97 (d, J = 8.5 Hz, 2H), 1.76 (d, J = 2.3 Hz, 2H), 1.65 (d, J = 12.5 Hz, 1H), 1.46 –
1.28 (m, 4H), 1.24 – 1.15 (m, 1H). 13C NMR (d6-DMSO) δ 161.9, 157.7, 152.3, 149.8, 123.6, 116.1, 42.7, 
38.9, 34.5, 25.7, 25.3.
2-(Chloromethyl)thieno[2,3-d]pyrimidin-4(3H)-one (11j). General procedure C. The reaction mixture was
concentrated under reduced pressure and the residue chromatographed on silica (50:50 petroleum
ether:EtOAc) which afforded the compound as a pale white solid (1.58 g, 21%). LCMS (m/z): 201.0 [M +
H]+. HPLC: tR 4.394 min. 1H NMR (d6-DMSO) δ 7.62 (d, J = 5.8 Hz, 1H), 7.40 (d, J = 5.8 Hz, 1H), 4.58 (s,
2H). 13C NMR (d6-DMSO) δ 163.8, 157.9, 152.8, 124.8, 123.6, 121.6, 42.7.
2-(Morpholinomethyl)-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one (12a).
General Procedure D. The residue was chromatographed on silica (1:99 Et3N:EtOAc) affording the compound
as a beige solid (2.52 g, 86%). LCMS (m/z): 292.1 [M + H]+. HPLC: tR 4.216 min. HRMS (m/z): C14H17N3O2S
requires 292.112[M + H]+; found 292.114. 1H NMR (CDCl3) δ 10.14 (s, 1H), 3.80 – 3.73 (m, 4H), 3.57 (s, 
2H), 3.09 – 3.02 (m, 2H), 2.94 (t, J = 7.3 Hz, 2H), 2.63 – 2.57 (m, 4H), 2.51 – 2.40 (m, 2H). 13C NMR (CDCl3)
δ 168.6, 158.2, 152.2, 140.1, 138.7, 119.5, 66.7, 60.6, 53.6, 29.5, 28.9, 27.
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2-(Morpholinomethyl)-3,5,6,7,8,9-hexahydro-4H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-one (12b).
General Procedure D. A precipitate was collected collected and recrystallised from CHCl3/i-PrOH affording
the compound as a white fluffy solid (3.29 g, 83%). LCMS (m/z): 320.1 [M + H]+. HPLC: tR 5.186 min. HRMS
(m/z): C16H21N3O2S requires 320.1433 [M + H]+; found 320.1427. 1H NMR (CDCl3) δ 10.09 (s, 1H), 3.83 – 
3.70 (m, 4H), 3.55 (s, 2H), 3.37 – 3.25 (m, 2H), 2.88 – 2.78 (m, 2H), 2.60 (s, 4H′), 1.89 (ddd, J = 8.3, 7.5, 4.3
Hz, 2H), 1.74 – 1.63 (m, 4H). 13C NMR (CDCl3) δ 161.8, 158.9, 137.8, 137.2, 130.1, 122.8, 66.8, 60.7, 53.6, 
32.6, 30.1, 28.1, 27.8, 27.4.
2-(Morpholinomethyl)-5,6,7,8,9,10-hexahydrocycloocta[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (12c).
General Procedure D. A precipitate was collected and recrystallised from CHCl3/i-PrOH to afford the
compound as a white fluffy solid (1.75 g, 63%). LCMS (m/z): 334.1 [M + H]+. HPLC: tR 5.489 min. HRMS
(m/z): C17H23N3O2S requires 334.1592 [M + H]+; found 334.1584. 1H NMR (CDCl3) δ 10.17 (s, 1H), 3.81 – 
3.71 (m, 4H), 3.54 (s, 2H), 3.13 – 3.05 (m, 2H), 2.90 – 2.81 (m, 2H), 2.67 – 2.51 (m, 4H), 1.78 – 1.61 (m,
4H), 1.45 (dd, J = 9.9, 4.7 Hz, 2H, 1.37 – 1.25 (m, 2H). 13C NMR (CDCl3) δ 163.1, 158.6, 152.4, 136.3, 134.4, 
122.2, 66.9, 60.8, 53.7, 31.9, 30.3, 27.1, 26.1, 25.8, 25.2.
2-(Morpholinomethyl)-6-phenylthieno[2,3-d]pyrimidin-4(3H)-one (12d). General Procedure D. Upon
cooling of the reaction mixture, a precipitate formed which was collected under vacuum and washed with cold
i-PrOH affording the compound as a white solid (2.71 g, 91%). LCMS (m/z): 328.1 [M + H]+. HPLC: tR 5.092
min. HRMS (m/z): C17H17N3O2S requires 328.1118 [M + H]+; found 328.1114. 1H NMR (d6-DMSO) δ 10.85 
(s, 1H), 7.78 (s, 1H), 7.78 – 7.73 (m, 2H), 7.46 (dd, J = 8.2, 6.8 Hz, 2H), 7.41 – 7.34 (m, 2H), 3.64 – 3.55
(m, 4H), 3.48 (s, 2H), 2.50 (dd, J = 6.1, 3.0 Hz, 4H). 13C NMR (d6-DMSO) δ 163.3, 157.8, 155.1, 139.3, 
132.8, 129.3, 128.6, 125.8, 124.7, 117.1, 66.1, 60.4, 53.0.
2-(Morpholinomethyl)-5-phenylthieno[2,3-d]pyrimidin-4(3H)-one (12e). General Procedure D. A
precipitate was collected under vacuum and recrystallised from CHCl3/i-PrOH to afford the desired compound
as bright yellow crystals (2.67 g, 83%). LCMS (m/z): 328.1 [M + H]+. HPLC: tR 4.853 min. HRMS (m/z):
C17H17N3O2S requires 328.1123 [M + H]+; found 328.1114. 1H NMR (CDCl3) δ 10.61 (s, 1H), 7.58 – 7.54 
(m, 2H), 7.44 – 7.35 (m, 3H), 7.10 (s, 1H), 3.71 – 3.66 (m, 4H), 3.53 (s, 2H), 2.56 – 2.50 (m, 4H). 13C NMR
(CDCl3) δ 166.7, 158.4, 154.2, 139.6, 135.4, 129.5, 127.9, 127.9, 120.3, 66.8, 60.7, 53.6.
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6-Benzyl-2-(morpholinomethyl)thieno[2,3-d]pyrimidin-4(3H)-one (12f). General Procedure D. The
residue was recrystallised from CHCl3/i-PrOH to afford the compound as beige crystals (2.47 g, 78%). LCMS
(m/z): 342.1 [M + H]+. HPLC: tR 5.208 min. HRMS (m/z): C18H19N3O2S requires 342.1278 [M + H]+; found
342.1271. 1H NMR (CDCl3) δ 10.09 (s, 1H), 7.35 – 7.30 (m, 4H), 7.26 (dt, J = 5.0, 1.4 Hz, 3H), 7.13 (t, J =
1.1 Hz, 1H), 4.15 (s, 2H), 3.78 – 3.74 (m, 4H), 3.55 (s, 2H), 2.61 – 2.54 (m, 4H). 13C NMR (CDCl3) δ 164.8, 
157.8, 153.2, 142.4, 138.8, 128.9, 128.8, 127.1, 123.9, 119.2, 66.8, 60.7, 53.7, 36.9.
5-Cyclohexyl-2-(morpholinomethyl)thieno[2,3-d]pyrimidin-4(3H)-one (12g). General Procedure D. i-
PrOH was introduced to a cooled reaction mixture and the resulting precipitate collected to afford the
compound as bright yellow crystals (1.56 g, 63% yield). LCMS (m/z): 334.1 [M + H]+. HPLC: tR 5.715 min.
HRMS (m/z): C17H23N3O2S requires 334.1587 [M + H]+; found 334.1584. 1H NMR (CDCl3) δ 10.15 (s, 1H), 
6.82 (s, 1H), 3.79 – 3.72 (m, 4H), 3.56 (s, 2H), 3.35 (tt, J = 11.6, 2.8 Hz, 1H), 2.62 – 2.56 (m, 4H), 2.05 (d, J
= 11.7 Hz, 2H), 1.86 – 1.71 (m, 3H), 1.54 – 1.41 (m, 2H), 1.33 (tt, J = 7.3, 3.5 Hz, 2H), 1.29 – 1.18 (m, 1H).
13C NMR (CDCl3) δ 166.1, 158.5, 153.3, 146.0, 121.3, 115.2, 66.9, 60.6, 53.7, 38.7, 33.8, 26.8, 26.4.
5,6-Dimethyl-2-(morpholinomethyl)thieno[2,3-d]pyrimidin-4(3H)-one (12h). General Procedure D. Upon
cooling of the reaction mixture, a formed precipitate was collected and washed with petroleum ether to afford
the desired compound as a bright yellow solid (2.74 g, 88%). LCMS (m/z): 280.2 [M + H]+. HPLC: tR 4.198
min. HRMS (m/z): C13H17N3O2S requires 280.1119 [M + H]+; found 280.1114. 1H NMR (CDCl3) δ 10.13 (s, 
1H), 3.79 – 3.71 (m, 4H), 3.53 (s, 2H), 2.63 – 2.56 (m, 4H), 2.46 (d, J = 0.6 Hz, 3H), 2.37 (s, 3H). 13C NMR
(CDCl3) δ 162.7, 158.7, 152.6, 130.3, 129.5, 122.9, 66.9, 60.7, 53.7, 13.2, 13.1.
6-Cyclohexyl-2-(morpholinomethyl)thieno[2,3-d]pyrimidin-4(3H)-one (12i). General Procedure D. The
solids were filtered from the cooled reaction mixture and recrystallised from i-PrOH to afford the compound
as white fluffy crystals (2.57 g, 60%). LCMS (m/z): 334.2 [M + H]+. HPLC: tR 5.603 min. HRMS (m/z):
C17H23N3O2S requires 334.1593 [M + H]+; found 334.1584. 1H NMR (CDCl3) δ 10.17 (s, 1H), 7.13 (d, J =
1.0 Hz, 1H), 3.79 – 3.71 (m, 4H), 3.55 (s, 2H), 2.83 – 2.73 (m, 1H), 2.61 – 2.53 (m, 4H), 2.10 – 2.02 (m, 2H),
1.83 (dd, J = 9.9, 2.9 Hz, 2H), 1.73 (ddd, J = 9.6, 5.6, 1.5 Hz, 1H), 1.50 – 1.32 (m, 4H), 1.30 – 1.18 (m, 1H).
13C NMR (CDCl3) δ 163.5, 158.0, 152.8, 150.2, 123.7, 115.8, 66.9, 60.8, 53.7, 39.9, 34.9, 26.3, 25.9.
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2-(Morpholinomethyl)thieno[2,3-d]pyrimidin-4(3H)-one (12j). General Procedure D. The residue was
chromatographed on silica (1:99 Et3N:EtOAc) which afforded the compound as a gold solid (1.10 g, 58%).
LCMS (m/z): 252.1 [M + H]+. HPLC: tR 3.009 min. HRMS (m/z): C11H13N3O2S requires 252.0803 [M + H]+;
found 252.0801. 1H NMR (CDCl3) δ 10.28 (s, 1H), 7.44 (d, J = 5.8 Hz, 1H), 7.21 (d, J = 5.8 Hz, 1H), 3.78 –
3.73 (m, 4H), 3.57 (s, 2H), 2.63 – 2.55 (m, 4H). 13C NMR (CDCl3) δ 165.3, 158.2, 153.8, 123.7, 123.1, 121.9, 
66.8, 60.7, 53.7.
4-((4-Chloro-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl)methyl)morpholine (13a).
General Procedure E. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the compound
as a brown oil (270 mg, 67%). LCMS (m/z): 310.1 [M + H]+. HPLC: tR 5.230 min. 1H NMR (CDCl3) δ 3.85 
(s, 1H), 3.78 – 3.75 (m, 2H), 3.17 – 3.11 (m, 2H), 3.07 – 3.02 (m, 2H), 2.63 – 2.56 (m, 4H), 2.56 – 2.47 (m,
1H). 13C NMR (CDCl3) δ 174.3, 160.5, 152.9, 144.6, 136.2, 124.6, 66.9, 64.9, 53.8, 30.3, 29.5, 27.5.
4-((4-Chloro-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-2-yl)methyl)morpholine
(13b). General Procedure E. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the
compound as a gold oil (2.62 g, 70%). LCMS (m/z): 338.1 [M + H]+. HPLC: tR 5.949 min. 1H NMR (CDCl3)
δ 3.61 (s, 2H), 3.56 – 3.49 (m, 2H), 3.14 – 3.03 (m, 2H), 2.77 – 2.66 (m, 2H), 2.42 – 2.34 (m, 4H), 1.69 (dd, 
J = 11.3, 5.9 Hz, 2H), 1.51 (ddd, J = 10.7, 9.4, 5.4 Hz, 4H). 13C NMR (CDCl3) δ 167.8, 159.4, 152.5, 143.1, 
131.7, 126.7, 66.3, 64.1, 53.3, 31.4, 29.6, 27.6, 26.5, 26.0.
4-((4-Chloro-5,6,7,8,9,10-hexahydrocycloocta[4,5]thieno[2,3-d]pyrimidin-2-yl)methyl)morpholine
(13c). General Procedure E. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the
compound as a gold oil (1.91 g, 67%). LCMS (m/z): 352.1 [M + H]+. HPLC: tR 6.259 min. 1H NMR (CDCl3)
δ 3.44 (s, 2H), 3.40 – 3.25 (m, 4H), 2.75 – 2.65 (m, 2H), 2.61 – 2.48 (m, 2H), 2.26 – 2.15 (m, 4H), 1.45 – 1.24 
(m, 4H), 1.08 (dd, J = 9.5, 4.8 Hz, 2H), 0.91 – 0.84 (m, 2H). 13C NMR (CDCl3) δ 168.2, 159.4, 152.0, 141.3, 
128.4, 125.8, 65.9, 63.8, 53.0, 30.8, 29.4, 27.2, 25.5, 24.5, 24.1.
4-((4-Chloro-6-phenylthieno[2,3-d]pyrimidin-2-yl)methyl)morpholine (13d). General Procedure E. The
residue was recrystallised from CHCl3/petroleum ether to afford the compound as pale white crystals (2.45 g,
90%). LCMS (m/z): 346.1 [M + H]+. HPLC: tR 6.418 min. 1H NMR (d6-DMSO) δ 8.08 (s, 1H), 7.96 (d, J =
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6.9 Hz, 2H), 7.58 – 7.48 (m, 3H), 4.67 (s, 2H), 3.89 (s, 4H), 3.60 – 3.26 (m, 4H). 13C NMR (d6-DMSO) δ 
167.7, 153.5, 145.9, 131.7, 130.2, 130.1, 129.5, 126.8, 114.9, 63.4, 59.9, 51.8.
4-((4-Chloro-5-phenylthieno[2,3-d]pyrimidin-2-yl)methyl)morpholine (13e). General Procedure E. The
residue was chromatographed on silica (1:99 Et3N:EtOAc) which afforded the compound as a gold solid 1.02
g, 96%). LCMS (m/z): 346.1 [M + H]+. HPLC: tR 5.595 min. 1H NMR (d6-DMSO) δ 7.95 (s, 1H), 7.68 – 7.29 
(m, 5H), 3.80 (s, 2H), 3.63 – 3.53 (m, 4H), 2.55 – 2.51 (m, 4H). 13C NMR (d6-DMSO) δ 169.72, 161.43, 
153.8, 134.9, 134.7, 130.0, 128.2, 127.8, 127.5, 124.7, 66.2, 63.7, 53.1.
4-((6-Benzyl-4-chlorothieno[2,3-d]pyrimidin-2-yl)methyl)morpholine (13f). General Procedure E. The
residue was recrystallised from CHCl3/i-PrOH to afford the compound as pale yellow crystals (1.55 g, 70%).
LCMS (m/z): 360.1 [M + H]+. HPLC: tR 6.261 min. 1H NMR (d6-DMSO) δ 7.34 (d, J = 4.4 Hz, 1H), 4.35 (s,
2H), 3.76 (s, 2H), 3.60 – 3.50 (m, 4H), 2.56 – 2.44 (m, 4H). 13C NMR (d6-DMSO) δ 168.5, 152.4, 148.2, 
138.7, 128.8, 128.7, 127.9, 126.9, 116.8, 114.9, 67.1, 65.9, 52.9, 36.1.
4-((4-Chloro-5-cyclohexylthieno[2,3-d]pyrimidin-2-yl)methyl)morpholine (13g). General Procedure E.
The residue was chromatographed on silica (1:99 Et3N:EtOAc) which afforded the compound as a gold oil
(1.14 g, 69%). LCMS (m/z): 352.1 [M + H]+. HPLC: tR 6.418 min. 1H NMR (CDCl3) δ 7.21 (d, J = 0.7 Hz,
1H), 3.88 (s, 2H), 3.82 – 3.73 (m, 4H), 3.45 – 3.32 (m, 1H), 2.68 – 2.57 (m, 4H), 2.11 (d, J = 12.8 Hz, 2H),
1.87 (d, J = 12.9 Hz, 2H), 1.80 (d, J = 12.9 Hz, 1H), 1.53 – 1.35 (m, 4H), 1.33 – 1.19 (m, 1H). 13C NMR
(CDCl3) δ 171.4, 161.1, 154.5, 141.3, 125.7, 120.9, 66.9, 64.7, 53.9, 38.8, 34.4, 26.8, 26.2.
4-((4-Chloro-5,6-dimethylthieno[2,3-d]pyrimidin-2-yl)methyl)morpholine (13h). General Procedure E.
The residue was recrystallised from CHCl3/i-PrOH to afford the compound as pale white crystals (1.55 g,
70%). LCMS (m/z): 298.1 [M + H]+. HPLC: tR 4.925 min. 1H NMR (CDCl3) δ 3.96 (s, 2H), 3.87 – 3.79 (m, 
4H), 2.76 (s, 4H), 2.53 (d, J = 0.5 Hz, 3H), 2.50 (s, 3H). 13C NMR (CDCl3) δ 168.9, 153.5, 136.4, 128.0, 
125.1, 118.4, 66.3, 63.9, 53.4, 14.3, 14.2.
4-((4-Chloro-6-cyclohexylthieno[2,3-d]pyrimidin-2-yl)methyl)morpholine (13i). The residue was
chromatographed on silica (1:99 Et3N:EtOAc) affording the compound as a gold oil which later solidified
under vacuum to produce a light yellow/white solid (1.64 g, 64%). LCMS (m/z): 352.1 [M + H]+. HPLC: tR
6.663 min. 1H NMR (CDCl3) δ 7.05 (d, J = 1.1 Hz, 1H), 3.85 (s, 2H), 3.78 – 3.73 (m, 4H), 2.95 – 2.83 (m,
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1H), 2.64 – 2.55 (m, 4H), 2.10 (dd, J = 13.4, 1.3 Hz, 2H), 1.91 – 1.83 (m, 2H), 1.80 – 1.71 (m, 1H), 1.57 –
1.35 (m, 4H), 1.32 – 1.21 (m, 1H). 13C NMR (CDCl3) δ 168.6, 160.9, 155.3, 153.3, 128.7, 113.7, 66.9, 65.0, 
53.8, 40.5, 34.8, 26.3, 25.8.
4-((4-Chlorothieno[2,3-d]pyrimidin-2-yl)methyl)morpholine (13j). General Procedure E. The residue was
chromatographed on silica (1:99 Et3N:EtOAc) which afforded the compound as a gold oil later solidifying
under vacuum (1.12 g, 73%). LCMS (m/z): 270.0 [M + H]+. HPLC: tR 1.169 min. 1H NMR (CDCl3) δ 7.58 
(d, J = 6.0 Hz, 1H), 7.41 (d, J = 6.0 Hz, 1H), 3.91 (s, 2H ), 3.81 – 3.74 (m, 4H), 2.70 – 2.60 (m, 4H). 13C NMR
(CDCl3) δ 169.5, 162.1, 155.1, 128.2, 127.9, 119.8, 66.9, 64.9, 53.9.
2-(Morpholinomethyl)-N-(3-(trifluoromethyl)phenyl)-6,7-dihydro-5H-
cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-amine (14a). General Procedure F. The residue was
chromatographed on silica (1:99 Et3N:EtOAc) and the resulting residue recrystallised from CHCl3-petroleum
ether to afford the title compound as a white powder (127 mg, 52%). LCMS (m/z): 435.1 [M + H]+. HPLC: tR
6.750 min. HRMS (m/z): C21H21F3N4OS requires 435.1467 [M + H]+; found 435.1464. 1H NMR (d6-acetone)
δ 8.49 (s, 1H), 8.13 (d, J = 8.2 Hz, 1H), 7.86 (s, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.40 (d, J = 7.7 Hz, 1H), 3.68
(s, 2H), 3.66 – 3.59 (m, 4H), 3.31 (ddd, J = 5.7, 3.5, 1.7 Hz, 2H), 3.09 – 2.99 (m, 2H), 2.63 – 2.58 (m, 4H),
2.58 – 2.49 (m, 2H). 13C NMR (d6-acetone) δ 173.4, 161.6, 154.7, 141.3, 137.8, 131.1 (q, J = 32.0 Hz), 130.2,
125.3 (q, J = 272.1 Hz), 125.1, 119.9 (d, J = 3.9 Hz), 118.2 (d, J = 4.1 Hz), 113.4, 67.5, 65.8, 54.5, 30.1, 29.6,
28.5.
2-(Morpholinomethyl)-N-(3-(trifluoromethyl)phenyl)-6,7,8,9-tetrahydro-5Hcyclohepta[4,5]thieno[2,3-
d]pyrimidin-4-amine (14b). General Procedure F. The residue was chromatographed on silica (1:99
Et3N:EtOAc) to afford the title compound as a gold oil (90.3 mg, 12%). LCMS (m/z): 463.1 [M + H]+. HPLC:
tR 7.226 min. HRMS (m/z): C21H21F3N4OS requires 463.1782 [M + H]+; found 463.1774. 1H NMR (CDCl3) δ 
8.10 (s, 1H), 7.75 (dd, J = 8.1, 1.7 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.22 (s, 1H),
3.76 – 3.73 (m, 4H), 3.74 (s, 2H), 3.16 – 3.08 (m, 2H), 2.93 – 2.89 (m, 2H), 2.67 – 2.59 (m, 4H), 1.98 – 1.78
(m, 4H), 1.88 – 1.79 (m, 2H). 13C NMR (CDCl3) δ 166.4, 160.1, 154.1, 139.6, 138.9, 131.3 (q, J = 32.4 Hz),
129.4, 129.3, 124.1 (q, J = 272.5 Hz), 123.6, 119.9 (q, J = 3.8 Hz), 117.5 (q, J = 3.9 Hz), 116.4, 67.0, 65.1,
53.8, 30.4, 30.3, 29.1, 26.9, 26.4.
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2-(Morpholinomethyl)-N-(3-(trifluoromethyl)phenyl)-5,6,7,8,9,10hexahydrocycloocta[4,5]thien o[2,3-
d]pyrimidin-4-amine (14c). General Procedure F. The residue was chromatographed on silica (1:99
Et3N:EtOAc) to afford the compound as gold oil (60.2 mg, 11%). LCMS (m/z): 477.2 [M + H]+. HPLC: tR
7.442 min. HRMS (m/z): C24H27F3N4O requires 477.194 [M + H]+; found 477.193.1H NMR (CDCl3) δ 8.23 
(s, 1H), 7.77 (dd, J = 8.1, 1.7 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 7.35 (s, 1H), 7.32 (d, J = 5.8 Hz, 1H), 3.77 (s,
2H), 3.78 – 3.74 (m, 4H), 3.07 (dd, J = 11.8, 5.5 Hz, 2H), 2.95 – 2.88 (m, 2H), 2.69 – 2.62 (m, 4H), 1.92 –
1.81 (m, 2H), 1.78 – 1.69 (m, 2H,0), 1.60 – 1.51 (m, 2H), 1.39 (dd, J = 10.5, 5.3 Hz, 2H). 13C NMR (CDCl3)
δ 167.0, 160.3, 153.9, 139.6, 138.3, 131.4 (q, J = 32.5 Hz), 129.4, 126.5, 124.1 (d, J = 272.5 Hz), 123.45,
119.9 (q, J = 3.8 Hz), 117.4 (q, J = 3.9 Hz), 115.2, 67.1, 65.3, 53.9, 31.7, 30.1, 28.0, 26.3, 26.2, 25.2.
2-(Morpholinomethyl)-6-phenyl-N-(3-(trifluoromethyl)phenyl)thieno[2,3-d]pyrimidin-4-amine (14d).
General Procedure F. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the title
compound as a gold solid (244 mg, 51%). LCMS (m/z): 471.1 [M + H]+. HPLC: tR 7.124 min. HRMS (m/z):
C24H21F3N4OS requires 471.1467 [M + H]+; found 471.1461. 1H NMR (d6-DMSO) δ 9.88 (s, 1H), 8.58 (s, 
1H), 8.25 (s, 1H), 8.18 (d, J = 8.18 Hz, 1H), 7.73 (d, J = 7.5 Hz, 2H), 7.62 (t, J = 8.0 Hz, 1H), 7.53 (t, J = 7.6
Hz, 2H), 7.43 (t, J = 7.8 Hz, 2H), 3.66 (s, 2H), 3.62 – 3.57 (m, 4H), 2.58 – 2.52 (m, 4H). 13C NMR (d6-DMSO)
δ 166.6, 161.5, 153.8, 140.5, 139.2, 133.0, 129.7, 129.4, 129.4 (d, J = 31.4 Hz) 128.8, 125.8, 124.3 (q, J =
272.4 Hz), 123.7, 118.9 (d, J = 3.8 Hz), 116.8, 116.6 (d, J = 4.1 Hz), 114.9, 66.2, 64.8, 53.3.
2-(Morpholinomethyl)-5-phenyl-N-(3-(trifluoromethyl)phenyl)thieno[2,3-d]pyrimidin-4-amine (14e).
General Procedure F. The residue was chromatographed on silica (1:29:70 Et3N:petroleum ether:EtOAc) to
afford the compound as a gold oil (307 mg, 75%). LCMS (m/z): 471.1 [M + H]+. HPLC: tR 7.195 min. HRMS
(m/z): C24H21F3N4OS requires 471.1465 [M + H]+; found 471.1461. 1H NMR (CDCl3) δ 8.08 (s, 1H), 7.60 
(dd, J = 6.4, 2.5 Hz, 3H), 7.55 (d, J = 2.2 Hz, 1H), 7.54 (d, J = 3.8 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.25 (dd,
J = 13.4, 5.5 Hz, 2H), 7.21 (s, 1H), 7.01 (s, 1H), 3.85 (s, 2H), 3.82 – 3.77 (m, 4H), 2.76 – 2.66 (m, 4H). 13C
NMR (CDCl3) δ 168.5, 161.9, 154.6, 139.3, 135.9, 133.77, 131.33 (q, J = 32.2 Hz), 129.6, 129.4, 129.3 (d, J
= 2.8 Hz), 123.3 (q, J = 272.2 Hz), 122.3, 121.5, 119.6 (q, J = 3.8 Hz), 116.5 (q, J = 4.0 Hz), 113.3, 67.0, 65.3,
53.8.
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6-Benzyl-2-(morpholinomethyl)-N-(3-(trifluoromethyl)phenyl)thieno[2,3-d]pyrimidin-4-amine (14f).
General Procedure F. The reaction precipitate was collected under vacuum and washed with cold i-PrOH to
afford the compound as a white solid (37.5 mg, 55%). LCMS (m/z): 485.2 [M + H]+. HPLC: tR 7.162 min.
HRMS (m/z): C25H23F3N4OS requires 485.1624 [M + H]+; found 485.1617. 1H NMR (d6-DMSO) δ 10.39 (s, 
1H), 8.36 (d, J = 8.5 Hz, 1H), 8.19 (s, 1H), 7.92 (s, 1H), 7.61 (t, J = 8.0 Hz, 1H), 7.45 (d, J = 7.7 Hz, 1H),
7.39 – 7.33 (m, 4H), 7.30 – 7.25 (m, 1H), 4.52 (s, 2H), 4.30 (s, 2H), 3.89 (s, 4H), 3.40 (s, 4H). 13C NMR (d6-
DMSO) δ 166.2, 153.9, 142.6, 139.9, 139.2, 129.8, 129.4, 129.1, 128.7, 128.7, 126.8, 125.3, 124.2 (q, J =
272.3 Hz), 119.6, 117.6 (d, J = 3.9 Hz), 117.4, 116.8, 63.2, 59.8, 51.8, 36.2.
5-Cyclohexyl-2-(morpholinomethyl)-N-(3-(trifluoromethyl)phenyl)thieno[2,3-d]pyrimidin-4-amine
(14g). General Procedure F. The residue was chromatographed on silica (1:29:70 Et3N:petroleum ether:
EtOAc) to afford the title compound as a yellow oil which later solidified under vacuum (260 mg, 66%).
LCMS (m/z): 477.2 [M + H]+. HPLC: tR 7.618 min. HRMS (m/z): C24H27F3N4OS requires 477.1937[M + H]+;
found 477.193. 1H NMR (CDCl3) δ 8.33 (s, 1H), 7.75 (dd, J = 8.0, 0.9 Hz, 1H), 7.49 (t, J = 7.9 Hz, 1H), 7.37
(d, J = 6.6 Hz, 2H), 7.01 (s, 1H), 3.80 (s, 2H), 3.79 – 3.75 (m, 4H), 2.86 (t, J = 9.6 Hz, 1H), 2.74 – 2.62 (m,
4H), 2.23 (d, J = 10.4 Hz, 2H), 2.04 – 1.98 (m, 2H), 1.89 (d, J = 12.9 Hz, 1H), 1.64 – 1.47 (m, 4H), 1.45 –
1.31 (m, 1H). 13C NMR (CDCl3) δ 169.7, 161.2, 154.7, 139.6, 138.8, 131.6 (q, J = 32.3 Hz), 129.6, 124.2 (q,
J = 272.4 Hz), 123.2, 120.1 (q, J = 3.8 Hz), 117.3 (q, J = 4.0 Hz), 117.2, 114.1, 67.1, 65.2, 53.9, 41.3, 34.2,
26.9, 26.1.
5,6-Dimethyl-2-(morpholinomethyl)-N-(3-(trifluoromethyl)phenyl)thieno[2,3-d]pyrimidin-4-amine
(14h). General Procedure F. The residue was chromatographed on silica (1:29:70 Et3N:petroleum
ether/:EtOAc) to afford the title compound as a gold oil (214 mg, 40%). LCMS (m/z): 423.2 [M + H]+. HPLC:
tR 6.577 min. HRMS (m/z): C20H21F3N4OS requires 423.1464 [M + H]+; found 423.1461. 1H NMR (CDCl3) δ 
8.20 (s, 1H), 7.81 (dd, J = 8.1, 1.2 Hz, 1H), 7.46 (t, J = 8.0 Hz, 1H), 7.38 (s, 1H), 7.34 (d, J = 7.8 Hz, 1H),
3.78 – 3.75 (m, 6H), 2.68 – 2.63 (m, 4H), 2.60 (s, 3H), 2.47 (s, 3H). 13C NMR (CDCl3) δ 166.8, 160.5, 154.3, 
139.5, 131.9, 131.4 (q, J = 32.3 Hz), 129.5, 123.8 (q, J = 272.2 Hz), 123.5 (d, J = 1.2 Hz), 120.0 (q, J = 3.8
Hz), 117.4 (q, J = 4.0 Hz), 116.1, 67.1, 65.3, 53.9, 14.6, 13.7.
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6-Cyclohexyl-2-(morpholinomethyl)-N-(3-(trifluoromethyl)phenyl)thieno[2,3-d]pyrimidin-4-amine
(14i). General Procedure F. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the
compound as a white solid (258 mg, 54 %). LCMS (m/z): 477.2 [M + H]+. HPLC: tR 7.666 min. HRMS (m/z):
C24H27F3N4OS requires 477.1942 [M + H]+; found 477.193. 1H NMR (400 MHz, d6-DMSO) δ 9.72 (s, 1H), 
8.57 (s, 1H), 8.17 (d, J = 8.3 Hz, 1H), 7.62 (d, J = 0.9 Hz, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.39 (d, J = 7.7 Hz,
1H), 3.64 (s, 2H), 3.61 – 3.56 (m, 4H), 2.90 (tt, J = 10.8, 5.5 Hz, 1H,A), 2.56 – 2.51 (m, 4H), 2.07 (d, J = 9.7
Hz, 2H), 1.81 (dd, J = 9.3, 3.0 Hz, 2H), 1.71 (d, J = 12.7 Hz, 1H), 1.51 – 1.35 (m, 4H), 1.26 (ddd, J = 17.7,
10.6, 6.0 Hz, 1H).13C NMR (d6-DMSO) δ 165.9, 160.5, 153.4, 148.5, 140.7, 129.7, 129.3 (d, J = 31.4 Hz),
124.3 (q, J = 272.1 Hz), 123.6, 118.7 (d, J = 3.8 Hz), 116.5 (d, J = 4.0 Hz), 115.6, 113.5, 66.2, 64.7, 53.2,
39.1, 34.4, 25.6, 25.4.
2-(Morpholinomethyl)-N-(3-(trifluoromethyl)phenyl)thieno[2,3-d]pyrimidin-4-amine (14j). General
Procedure F. The precipitate was filtered and washed with cold i-PrOH affording the compound as a brown
solid (199 mg, 45%). LCMS (m/z): 395.1 [M + H]+. HPLC: tR 5.894 min. HRMS (m/z): C18H17F3N4OS
requires 395.1106 [M + H]+; found 395.1148. 1H NMR (d6-DMSO) δ 10.68 (s, 1H), 8.43 (d, J = 8.5 Hz, 1H),
8.29 (d, J = 5.9 Hz, 2H), 7.82 (d, J = 6.0 Hz, 1H), 7.62 (t, J = 8.0 Hz, 1H), 7.46 (d, J = 7.7 Hz, 1H), 4.56 (s,
2H), 3.92 (s, 4H), 3.40 (s, 4H). 13C NMR (d6-DMSO) δ 166.6, 154.7, 139.9, 129.7, 129.2 (d, J = 31.6 Hz),
128.8, 125.4, 124.7, 124.2 (q, J = 272.4 Hz), 120.3, 119.7 (d, J = 3.9 Hz), 117.7 (d, J = 3.9 Hz), 116.4, 63.3,
59.8, 51.9
6-Benzyl-N,N-dimethyl-2-(morpholinomethyl)thieno[2,3-d]pyrimidin-4-amine (15). General Procedure
F. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the compound as a gold oil (91
mg, 33%). LCMS (m/z): 369.2 [M + H]+. HPLC: tR 6.012 min, 93% purity (214 nm). HRMS (m/z):
C20H24N4OS requires 369.1747 [M + H]+; found 369.1744. 1H NMR (CDCl3) δ 7.30 (dd, J = 9.7, 4.8 Hz, 1H),
7.26 – 7.20 (m, 3H), 7.11 (s, 1H), 4.14 (s, 2H), 3.80 – 3.72 (m, 4H), 3.69 (s, 2H), 3.32 (s, 6H), 2.71 – 2.60 (m,
1H). 13C NMR (CDCl3) δ 169.6, 160.7, 160.0, 157.6, 139.1, 138.2, 128.6, 128.5, 126.7, 118.7, 114.5, 66.8, 
65.0, 53.6, 39.8, 36.9.
2-(Morpholinomethyl)-N-phenyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (16a).
General Procedure F. The residue was eluted through a silica gel column (99:1 EtOAc:Et3N) and proceeded
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to afford the title compound as a light pink oil which later solidified at room temperature (48.8 mg, 20%). mp:
129-135 ˚C. LCMS (m/z): 381.2 [M + H]+. HPLC: tR 6.294 min. HRMS (m/z): C21H24N4OS requires 381.1748
[M + H]+; found 381.1744. 1H NMR (CDCl3) δ 7.76 – 7.72 (m, 2H), 7.39 – 7.33 (m, 2H), 7.17 (s, 1H), 7.13 
– 7.07 (m, 1H), 3.80 – 3.77 (m, 4H),), 3.76 (s, 2H), 3.10 – 3.02 (m, J = 6.0 Hz, 2H), 2.88 – 2.78 (m, 2H), 2.69
– 2.62 (m, 4H), 2.02 – 1.96 (m, 2H), 1.96 – 1.89 (m, 2H). 13C NMR (CDCl3) δ 167.0, 160.7, 154.7, 138.9, 
134.4, 128.9, 124.4, 123.5, 120.5, 114.9, 67.0, 65.1, 53.9, 26.5, 25.5, 22.6, 22.5.
N-(3-Fluorophenyl)-2-(morpholinomethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-
amine (16b). General Procedure F. Chromatographed on silica (1:99 EtOAc:Et3N) to give the final product
as a yellow/orange solid (90.2 mg, 17%). mp: 141-150 ˚C. LCMS (m/z): 399.2 [M + H]+. HPLC: tR 6.569 min.
HRMS (m/z): C21H23FN4OS requires 399.1654 [M + H]+; found 399.1649. 1H NMR (CDCl3) δ 7.97 (dt, J =
11.5, 2.1 Hz, 1H), 7.32 – 7.26 (m, 1H), 7.24 – 7.19 (m, 2H), 6.80 (td, J = 8.2, 1.7 Hz, 1H), 3.83 – 3.80 (m,
4H), 3.80 (s, 2H), 3.06 (t, J = 5.7 Hz, 2H), 2.86 (t, J = 5.7 Hz, 2H), 2.72 – 2.65 (m, 4H), 2.02 – 1.97 (m, 2H),
1.97 – 1.91 (m, 2H). 13C NMR (CDCl3) δ 165.8 (d, J = 247.2 Hz), 161.9, 160.7, 154.4, 140.7 (d, J = 11.2 Hz),
134.9, 129.9 (d, J = 9.7 Hz), 124.3, 115.2 (d, J = 2.7 Hz), 115.1, 109.9 (d, J = 21.6 Hz), 107.78 d, J = 27.1
Hz), 67.1, 65.1, 53.9, 26.5, 25.6, 22.6, 22.5.
N-(3-Methoxyphenyl)-2-(morpholinomethyl)-5,6,7,8-tetrahydrobenzo [4,5]thieno[2,3-d]pyrimidin-4-
amine (16c). General Procedure F. This residue was purified using column chromatography (50:50 petroleum
ether/EtOAc) to afford the final product as a yellow oil (60.5 mg, 18%). 1H NMR (CDCl3) δ 7.65 (s, 1H, H), 
7.25 (t, J = 8.1 Hz, 1H), 7.18 (s, 1H), 7.12 (ddd, J = 8.2, 2.1, 0.8 Hz, 1H), 6.65 (ddd, J = 8.2, 2.5, 0.8 Hz, 1H),
3.86 (s, 3H), 3.81 – 3.76 (m, J = 8.3, 3.5 Hz, 6H), 3.06 (t, J = 5.9 Hz, 2H), 2.84 (t, J = 5.9 Hz, 2H), 2.67 (s,
4H), 2.03 – 1.96 (m, 2H), 1.96 – 1.89 (m, 2H). LCMS (m/z): 411.3 [M + H]+. HPLC: tR 6.521 min. HRMS
(m/z): C22H26N4O2S requires 411.1853 [M + H]+; found 411.1849. 13C NMR (CDCl3) δ 167.0, 160.2, 154.6, 
140.2, 134.6, 129.6, 124.4, 115.1, 112.5, 108.7, 106.6, 66.9, 65.2, 60.4, 55.3, 53.8, 26.4, 25.5, 22.6, 22.4.
3-((2-(Morpholinomethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)amino)phenol (17).
To a solution of N-(3-methoxyphenyl)-2- (morpholinomethyl)-5,6,7,8 tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-4-amine (195 mg, 475 µmol) in DCM (4.00 mL) at 0 °C was added BBr3 (1 M in DCM) (2.37
mL, 2.37 mmol). The mixture was stirred at r.t. under a N2 environment overnight, and then poured into ice-
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water. The solution was adjusted to pH 6 by addition of sat.NaHCO3. The DCM was removed under reduced
pressure and the aqueous residue extracted with EtOAc (3 x 20 mL). The combined organic extracts were
washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. The resulting residue was eluted
through a silica gel column (5:95 MeOH:DCM) to give the title compound as a white/grey solid (100 mg,
53%). mp: 98-105˚C. LCMS (m/z): 397.2 [M + H]+. HPLC: tR 5.850 min. HRMS (m/z): C21H24N4O2S requires
397.1699 [M + H]+; found 397.1693. 1H NMR (CDCl3) δ 8.37 (s, 1H), 7.73 (t, J = 2.0 Hz, 1H), 7.14 (s, 1H),
7.11 (t, J = 8.1 Hz, 1H), 6.87 (ddd, J = 8.0, 2.0, 0.7 Hz, 1H), 6.56 (ddd, J = 8.1, 2.3, 0.7 Hz, 1H), 3.79 (s, 2H),
3.78 – 3.73 (m, 4H), 2.98 (t, J = 5.4 Hz, 2H), 2.80 – 2.72 (m, 6H), 1.98 – 1.83 (m, 4H).13C NMR (CDCl3) δ  
166.4, 160.3, 157.4, 154.5, 139.8, 134.4, 129.7, 124.6, 115.1, 111.5, 111.1, 108.3, 66.8, 64.0, 52.8, 26.4, 25.5,
22.5, 22.4.
N-Methyl-2-(morpholinomethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (18).
General Procedure F. Upon completion of reaction the reaction vessel was stored at -4 °C overnight.
Precipitates were collected and washed with cold i-PrOH to afford the compound as light brown crystals (300
mg, 76%). LCMS (m/z): 319.1[M + H]+. HPLC: tR 5.162 min. HRMS (m/z): C16H22N4OS requires 319.1593
[M + H]+; found 319.1587. 1H NMR (CDCl3) δ 5.23 (dd, J = 9.4, 5.2 Hz, 1H), 3.82 – 3.74 (m, 4H), 3.71 (s,
2H), 3.10 (d, J = 4.8 Hz, 3H), 2.92 – 2.85 (m, 2H), 2.82 – 2.75 (m, 2H), 2.70 – 2.65 (m, 4H), 1.98 – 1.81 (m,
4H). 13C NMR (CDCl3) δ 165.9, 161.0, 158.0, 132.8, 125.2, 114.6, 67.1, 65.4, 53.9, 28.1, 26.5, 25.5, 22.7.
N,N-Diethyl-2-(morpholinomethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (19).
General Procedure F. The reaction mixture was concentrated under reduced pressure and the residue
chromatographed on silica (5% MeOH-DCM) to afford the compound as a gold oil (299 mg, 90%). LCMS
(m/z): 361.2 [M + H]+. HPLC: tR 5.162 min. HRMS (m/z): C19H28N4OS requires 361.2055 [M + H]+; found
361.2057. 1H NMR (CDCl3) δ 3.71 (t, J = 4.7 Hz, 6H), 3.41 (q, J = 7.0 Hz, 4H), 2.90 – 2.76 (m, 4H), 2.65 –
2.55 (m, 4H), 1.92 – 1.82 (m, 2H), 1.79 – 1.68 (m, 2H), 1.08 (t, J = 7.0 Hz, 6H). 13C NMR (CDCl3) δ 168.9, 
161.7, 159.1, 133.7, 127.4, 120.0, 66.9, 65.0, 53.6, 44.7, 26.6, 25.8, 23.1, 22.9, 12.5.
4-((4-(3-(Trifluoromethyl)phenoxy)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-
yl)methyl)morpholine16 (20). A mixture of 4-((4-chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-2-yl)methyl)morpholine (350 mg, 1.08 mmol), 3-(trifluoromethyl)phenol (135 µL, 1.11 mmol),
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K2CO3 (299 mg, 2.16 mmol), and tris[2-(2-methoxyethoxy)ethyl]amine (TRIDENT) (34.0 µL, 108 µmol)
were taken up in i-PrOH and irradiated at 40 W for 6 h in an 8 mL pressure tube. The reaction mixture was
diluted with water, and extracted with DCM. The combined organic extracts were dried and concentrated in
vacuo. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the title compound as pale
yellow oil (351 mg, 72%). LCMS (m/z): 450.1 [M + H]+. HPLC: tR 7.432 min. HRMS (m/z): C22H22F3N3O2S
requires 450.1468 [M + H]+; found 450.1458. 1H NMR (CDCl3) δ 7.56 – 7.48 (m, 3H), 7.41 (dt, J = 7.4, 1.7
Hz, 1H), 3.72 – 3.60 (m, 6H), 3.04 (t, J = 4.8 Hz, 2H), 2.85 (t, J = 4.8 Hz, 2H), 2.54 – 2.50 (m, 4H), 1.96 –
1.85 (m, 4H). 13C NMR (CDCl3) δ 169.6, 162.2, 160.5, 152.7, 136.2, 131.9 (q, J = 32.9 Hz), 130.0, 126.8,
125.3 (d, J = 0.8 Hz), 123.7 (q, J = 272.4 Hz), 122.0 (q, J = 3.8 Hz), 119.1 (q, J = 3.9 Hz), 117.5, 66.8, 64.3,
53.6, 25.8, 25.6, 22.9, 22.4.
5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one33 (21). Ethyl-2-amino-4,5,6,7-
tetrahydrobenzothiophene-3-carboxylate (4.05 g, 17.8 mmol) was taken up in formamide (20 mL) and heated
to 170 °C under a nitrogen atmosphere. The heating was continued for 12 h and the progress of the reaction
was monitored by TLC. The reaction mixture was allowed to cool to r.t., and the precipitated solids were
collected and washed with petroleum spirits to afford the compound as brown crystals (3.12 g, 85%). LCMS
(m/z): 207.1 [M + H]+. HPLC: tR 5.537 min. HRMS (m/z): C10H10N2OS requires 207.0585 [M + H]+; found
207.0587. 1H NMR (d6-DMSO) δ 7.99 (s, 1H), 2.86 (t, J = 5.9 Hz, 2H), 2.73 (t, J = 5.8 Hz, 2H), 1.88 – 1.64
(m, 4H). 13C NMR (d6-DMSO) δ 162.4, 157.6, 144.8, 132.1, 130.8, 122.6, 25.3, 24.4, 22.4, 21.7.
4-Chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (22). General Procedure E. The residue
was chromatographed on silica (99:1 EtOAc:Et3N) which afforded the compound as a gold solid (1.85 g,
68%). LCMS (m/z): 225.1 [M + H]+. HPLC: tR 8.139 min. 1H NMR (CDCl3) δ 8.70 (s, 1H), 3.09 (t, J = 4.3
Hz, 2H), 2.88 (dd, J = 5.0, 3.5 Hz, 2H), 1.92 (dt, J = 6.1, 2.9 Hz, 4H). 13C NMR (CDCl3) δ 169.02, 153.3, 
151.7, 139.7, 128.9, 127.3, 26.4, 26.2, 22.5, 22.3.
N-(3-(Trifluoromethyl)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (23a).
General Procedure F. The crude reaction was concentrated under reduced pressure and the residue
chromatographed on silica eluting with (1:29:70 Et3N:petroleum ether:EtOAc) to afford the compound as an
oil which later solidified under vacuum to give a beige solid (265 mg, 68%). LCMS (m/z): 350.1[M + H]+.
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HPLC: tR 8.367 min. HRMS (m/z): C17H14F3N3S requires 350.0936 [M + H]+; found 350.0933. 1H NMR
(CDCl3) δ 8.52 (s, 1H), 7.96 (s, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.36 (d, J = 7.8 Hz,
1H), 7.22 (s, 1H), 3.08 (t, J = 6.0 Hz, 1H), 2.86 (t, J = 6.0 Hz, 1H), 2.05 – 1.91 (m, 4H). 13C NMR (CDCl3) δ 
166.7, 15.6, 152.4, 139.3, 135.5, 131.5 (d, J = 32.4 Hz), 129.64, 126.1 (d, J = 1.0 Hz), 124.1 (q, J = 272.5 Hz),
120.3 (q, J = 3.8 Hz), 117.5 (q, J = 3.9 Hz), 116.8, 26.6, 25.6, 22.6, 22.4.
N,N-Diethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (23b). General procedure F.
The solution was concentrated in vacuo and the residue chromatographed on silica (4:1 EtOAc:petroleum
ether) which afforded the desired compound as a light gold oil that solidified under high vacuum to give a
pale yellow solid (233 mg, 80%). mpexp: 60-62 °C. LCMS (m/z): 262.1 [M + H]+. HPLC: tR 6.281 min. HRMS
(m/z): C14H19N3S requires 262.1376 [M + H]+; found 262.1372. 1H NMR (CDCl3) δ 8.50 (s, 1H), 3.46 (q, J =
7.1 Hz, 4H), 2.96 – 2.82 (m, 4H), 1.97 – 1.90 (m, 2H), 1.84 – 1.76 (m, 2H), 1.13 (t, J = 7.1 Hz, 6H),). 13C
NMR (CDCl3) δ 168.3, 162.1, 151.3, 134.2, 127.7, 122.1, 44.9, 26.6, 25.8, 23.0, 22.9, 12.4. 
2-(Piperidin-1-ylmethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (24).
General procedure D. The reaction mixture was poured into water. The formed precipitates were collected
under vacuum filtration and recrystallised from DMF. The mother liquor was extracted with EtOAc, washed
with water, brine and the combined organic extracts concentrated in vacuo. The residue was chromatographed
on silica (1:99 MeOH:EtOAc) to afford the target compound as cream white solid (350 mg, 73%), mp: 182-
184 ˚C. LCMS (m/z): 304.2 [M + H]+. HPLC: tR 5.228 min. HRMS (m/z): C16H21N3OS requires 303.1356 [M
+ H]+; found 303.14. 1H NMR  δ 9.95 (s, 1H), 3.46 (s, 2H), 3.04 – 2.97 (m, 2H), 2.77 – 2.73 (m, 2H), 2.54 – 
2.44 (m, 4H), 1.92 – 1.78 (m, 4H), 1.62 (m, 4H), 1.48 (d, J = 5.2 Hz, 2H). 13C NMR (CDCl3) δ 163.7, 158.3, 
153.8, 132.8, 131.5, 121.9, 60.8, 54.8, 25.9, 25.6, 25.1, 23.7, 23.0, 22.3.
4-Chloro-2-(piperidin-1-ylmethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (25).
General Procedure E. The residue was eluted through a silica gel column (99:1 EtOAc:Et3N) which proceeded
to give the compound as a golden oil (154 mg, 41%). LCMS (m/z): 324.1 [M + H]+. HPLC: tR 6.231 min.
HRMS (m/z): C16H20ClN3S requires 322.114 [M + H]+; found 322.1139. 1H NMR (CDCl3) δ 3.80 (s, 2H), 
3.06 (t, J = 4.2 Hz, 2H), 2.84 (t, J = 4.2 Hz, 2H), 2.52 – 2.49 (m, 4H), 1.93 – 1.86 (m, 4H), 1.67 – 1.57 (m,
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4H), 1.49 – 1.36 (m, 2H). 13C NMR (CDCl3) δ 169.4, 161.4, 152.9, 138.9, 126.9, 126.9, 65.2, 54.7, 26.3, 26.0, 
25.7, 24.1, 22.5, 22.2.
2-(Piperidin-1-ylmethyl)-N-(3-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-4-amine (26). General Procedure F. This residue was purified on silica gel (99:1 EtOAc:Et3N)
to give the final product as a yellow oil which later solidified at room temperature (100 mg, 24%). mp: 121-
126˚C. LCMS (m/z): 447.3 [M + H]+. HPLC: tR 7.602 min. HRMS (m/z): C23H25F3N4S requires 447.1828 [M
+ H]+; found 447.1825. 1H NMR  δ 8.17 (s, 1H), 7.93 (dd, J = 8.1, 1.6 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.34
– 7.31 (d, J = 7.7 Hz, 1H), 7.26 (s, 1H), 3.77 (s, 2H), 3.09 (t, J = 6.0 Hz, 2H), 2.87 (t, J = 6.0 Hz, 2H), 2.58 (s,
4H), 2.04 – 1.97 (m), 1.98 – 1.94 (m, 2H), 1.66 (dt, J = 11.2, 5.6 Hz, 4H), 1.48 – 1.39 (m, 2H). 13C NMR
(CDCl3)  δ  167.5, 161.4, 154.2, 139.7, 135.0, 131.4 (q, J = 32.3 Hz), 129.5, 124.2, 124.1 (q, J = 272.4 Hz),
123.2, 119.7 (q, J = 3.8 Hz), 117.1 (q, J = 4.0 Hz), 115.1, 65.8, 54.8, 26.6, 26.0, 25.7, 24.3, 22.7, 22.5.
2-(Tetrahydro-4H-pyran-4-ylidene)acetonitrile35 (29). To a suspension of sodium hydride (60% mineral
dispersion oil) (2.37 g, 59.3 mmol) in diethyl ether (150 mL) cooled to 0 °C was added diethyl
cyanomethylphosphonate (9.55 mL, 59.3 mmol) dropwise followed by a solution of tetrahydro-4H-pyran-4-
one (5.00 mL, 53.9 mmol) in diethyl ether (150 mL). After the addition was completed the reaction was
warmed to room temperature and stirred overnight. H2O and EtOAc were added, the organic layer was
separated, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to provide the compound
as a brown oil. The crude oil was then subjected to vacuum distillation (20 mbar) to reveal the title compound
as a transparent oil which crystallised upon standing. This distillate was dissolved in hot petroleum ether and
left in the fridge overnight to recrystallise. The crystals were collected and dried to afford the desired
compound as a white crystalline solid (2.56 g, 39%). LCMS (m/z): 124.2 [M + H]+. HPLC: tR 3.390 min. 1H
NMR (CDCl3) δ 5.19 – 5.16 (m, 1H), 3.81 – 3.71 (m, 4H), 2.67 – 2.60 (m, 2H), 2.43 – 2.37 (m, 2H). 13C NMR
(CDCl3) δ 162.7, 116.2, 93.6, 68.3, 68.1, 35.9, 33.7. 
2-(Tetrahydro-2H-pyran-4-yl)acetonitrile35 (30). To a solution of 2-(tetrahydro-4H-pyran-4-
ylidene)acetonitrile (2.65 g, 20.8 mmol), in ethyl acetate (25 mL) & acetic acid (1 mL), stirred under N2 was
added 10% Pd/C (84.0 mg, 4.17 mmol). The reaction mixture was evacuated under reduced pressure, purged
with hydrogen and stirred for 5 h at rt under 1 atm of pressure. TLC showed consumption of the starting
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material after 5 hours. The reaction was filtered (Celite®) and the filtrate was concentrated in vacuo to provide
the compound as pale yellow oil which was used for the next reaction without any further purification (2.61
g, quantitative yield). 1H NMR (CDCl3) δ 4.04 – 3.98 (m, 2H), 3.40 (td, J = 11.9, 2.1 Hz, 2H), 2.32 (d, J = 6.8
Hz, 2H), 1.93 (qdd, J = 10.8, 7.0, 3.9 Hz, 2H), 1.75 (ddd, J = 12.6, 3.5, 1.6 Hz, 2H), 1.51 – 1.38 (m, 2H). 13C
NMR (CDCl3) δ 118.1, 67.3, 32.3, 32.1, 24.4. 
2-((Tetrahydro-2H-pyran-4-yl)methyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one
(31). General Procedure C. The reaction mixture was filtered directly and the solid washed with petroleum
ether to obtain the desired compound as a beige solid (4.23 g, 93%). mp: 250-252 °C. LCMS (m/z): 255.1 [M
+ H]+. HPLC: tR 6.858 min. HRMS (m/z): C11H11ClN2OS requires 255.0354 [M + H]+; found 255.0353.1H
NMR (d6-DMSO) δ 7.44 (s, 1H), 4.56 (s, 2H), 2.85 (t, J = 5.8 Hz, 2H), 2.73 (t, J = 5.8 Hz, 2H), 1.76 (ddd, J
= 7.5, 6.8, 4.4 Hz, 4H). 13C NMR (d6-DMSO) δ 163.1, 158.5, 156.0, 131.0, 130.5, 120.4, 66.8, 40.8, 33.8, 
32.2, 25.3, 24.4, 22.5, 21.8.
4-Chloro-2-((tetrahydro-2H-pyran-4-yl)methyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine
(32). General Procedure E. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the
compound as a gold oil (350 mg, 24%). LCMS (m/z): 323.2 [M + H]+. HPLC: tR 9.066 min, >95% purity (254
nm). 1H NMR (CDCl3) δ 3.93 (dd, J = 11.5, 2.4 Hz, 2H), 3.38 (td, J = 11.7, 2.3 Hz, 2H), 3.06 (d, J = 2.1 Hz,
2H), 2.91 (d, J = 7.2 Hz, 2H), 2.85 (d, J = 2.1 Hz, 2H), 2.28 – 2.17 (m, 1H), 1.90 (dt, J = 6.0, 2.9 Hz, 4H),
1.60 – 1.52 (m, 2H), 1.51 – 1.39 (m, 2H). 13C NMR (CDCl3) δ 169.3, 163.4, 152.9, 138.2, 126.9, 126.3, 67.8, 
45.7, 35.1, 32.8, 26.3, 25.9, 22.5, 22.3.
2-((Tetrahydro-2H-pyran-4-yl)methyl)-N-(3-(trifluoromethyl)phenyl)-5,6,7,8-
tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (33a). General Procdedure F. The crude reaction
mixture was evaporated under reduced pressure and the residue chromatographed on silica (1% MeOH-
CHCl3) which furnished the title compound as a white foam (160 mg, 48%). LCMS (m/z): 448.2 [M + H]+.
HPLC: tR 7.945 min. HRMS (m/z): C23H24F3N3OS requires 448.1673 [M + H]+; found 448.1665. 1H NMR
(CDCl3) δ 8.31 (s, 1H), 7.72 (dd, J = 8.1, 1.7 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.36 – 7.33 (m, 1H), 7.24 (s,
1H), 3.95 (dd, J = 11.5, 2.4 Hz, 2H), 3.41 (td, J = 11.8, 2.1 Hz, 2H), 3.07 (t, J = 6.0 Hz, 2H), 2.84 (dd, J =
13.1, 6.7 Hz, 4H), 2.26 (dqd, J = 15.1, 7.5, 3.7 Hz, 1H), 2.03 – 1.90 (m, 4H), 1.63 (dd, J = 13.0, 1.9 Hz, 2H),
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1.52 – 1.43 (m, 2H). 13C NMR (CDCl3) δ 167.3, 163.4, 154.2, 139.5, 134.3, 131.3, (q, J = 32.2 Hz), 124.3,
124.1, (q, J = 272.5 Hz) 123.0, 119.7, (q, J = 3.8 Hz), 117.2, (q, J = 4.0 Hz), 114.5, 67.9, 46.2, 34.9, 32.9,
26.5, 25.5, 22.6, 22.5.
N,N-Diethyl-2-((tetrahydro-2H-pyran-4-yl)methyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-4-amine (33b). General procedure F. Chromatographed on silica (50:50 petroleum ether:EtOAc)
furnishing the target compound as a gold oil (150 mg, quantitative yield). LCMS (m/z): 360.2 [M + H]+.
HPLC: tR 6.664 min. HRMS (m/z): C20H29N3OS requires 360.2107 [M + H]+; found 360.2104. 1H NMR
(CDCl3) δ 3.94 (dd, J = 11.4, 2.4 Hz, 2H), 3.44 (dd, J = 14.1, 7.1 Hz, (m, 4H), 3.42 – 3.34 (m, 2H), 2.89 (t, J
= 5.9 Hz, 2H), 2.84 (t, J = 6.3 Hz, 2H), 2.79 (d, J = 7.2 Hz, 2H), 2.27 – 2.15 (m, 1H), 1.96 – 1.88 (m, 2H),
1.81 – 1.74 (m, 2H), 1.59 (dd, J = 13.0, 1.7 Hz, 2H), 1.44 (ddd, J = 11.9, 10.3, 6.0 Hz, m, 2H), 1.12 (t, J = 7.0
Hz, 6H). 13C NMR (CDCl3) δ 168.9, 162.0, 161.9, 132.9, 127.6, 119.6, 68.1, 45.9, 44.9, 34.9, 33.0, 26.7, 25.8, 
23.1, 23.0, 12.5.
4-Morpholinobutanenitrile36 (35b). Morpholine (3.66 mL, 42.3 mmol) and 4-chlorobutanenitrile (2.00 mL,
21.6 mmol) were taken up in toluene (30 mL) and stirred at reflux temperature for 7 h. The reaction mixture
was filtered directly and the solids washed with CH2Cl2. The filtrate was acidified with 1M KHSO4 solution
and extracted with further CH2Cl2, and the organic extracts were discarded. The aqueous phase was then
adjusted to pH 12 with 1M NaOH and extracted with CH2Cl2 (3 x 25 mL). The organic extracts were dried
over anhydrous Na2SO4, and concentrated in vacuo to yield the compound as a transparent oil which was
utilised without further purification (2.12 g, 65%). LCMS (m/z): 155.1 [M + H]+. 1H NMR (CDCl3) δ 3.77 – 
3.66 (m, 4H), 2.53 – 2.37 (m, 8H), 1.83 (p, J = 6.9 Hz, 2H). 13C NMR (CDCl3) δ 119.8, 66.9, 56.7, 53.5, 22.5, 
14.9.
5-Morpholinopentanenitrile36 (35c). Morpholine (6.93 mL, 80.4 mmol) and 5-chlorovaleronitrile (4.50 mL,
40.2 mmol) were taken up in toluene (50 mL) and stirred at reflux temperature for 8 h. The reaction mixture
was filtered directly and the solids washed with CH2Cl2. The filtrate was acidified with 1M KHSO4 solution
and extracted with further CH2Cl2, and the organic extracts were discarded. The aqueous phase was then
adjusted to pH 12 with 1M NaOH and extracted with CH2Cl2 (3 x 30 mL). The organic extracts were dried
over anhydrous Na2SO4, and concentrated in vacuo to yield the compound as a transparent oil which was
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utilised without further purification (2.93 g, 43%). LCMS (m/z): 169.2 [M + H]+. 1H NMR (CDCl3) δ 3.77 – 
3.61 (m, 4H), 2.52 – 2.29 (m, 8H), 1.80 – 1.57 (m, 4H). 13C NMR (CDCl3) δ 119.7, 67.0, 57.8, 53.7, 25.4, 
23.4, 17.1.
2-(2-Chloroethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (36a). General
procedure C. The reaction was allowed to cool and the precipitate was collected, washed with cold 1,4-
dioxane, triturated with petroleum ether, filtered and dried to afford the compound as a beige powder (4.95 g,
83%). LCMS (m/z): 269.1 [M + H]+. HPLC: tR 6.677 min. 1H NMR (d6-DMSO) δ 12.38 (s, 1H), 3.98 (t, J =
6.6 Hz, 2H), 3.09 (t, J = 6.6 Hz, 2H), 2.84 (t, J = 5.8 Hz, 2H), 2.71 (t, J = 5.8 Hz, 2H), 1.83 – 1.67 (m, 4H).
13C NMR (d6-DMSO) δ 162.6, 158.4, 154.2, 131.6, 130.7, 120.8, 41.5, 36.6, 25.3, 24.4, 22.5, 21.8. 
2-(3-Chloropropyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (36b). General
procedure C. The reaction mixture was allowed to cool and the formed precipitate was collected and washed
with cold 1,4-dioxane to yield a light brown solid (3.16 g, 60%). LCMS (m/z): 283.1 [M + H]+. HPLC: tR
7.018 min. 1H NMR (d6-DMSO) δ 12.29 (s, 1H), 3.70 (t, J = 6.5 Hz, 1H), 2.85 (t, J = 5.8 Hz, 2H), 2.78 – 2.73
(m, 2H), 2.73 – 2.68 (m, 2H), 2.15 (dq, J = 13.6, 6.6 Hz, 2H), 1.77 (ddt, J = 8.6, 5.2, 2.6 Hz, 4H). 13C NMR
(d6-DMSO) δ 162.6, 158.5, 156.4, 131.2, 130.6, 120.6, 44.6, 30.9, 29.3, 25.3, 24.4, 22.5, 21.8. 
2-(4-Chlorobutyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (36c). The reaction
mixture was allowed to cool and water (150 mL) was added. The precipitate was collected, washed with
MeOH, and recrystallised from DMF to afford the compound as light brown crystals (6.56 g, 83% yield).
LCMS (m/z): 297.1 [M + H]+. HPLC: tR 7.276 min. 1H NMR (d6-DMSO) δ 12.22 (s, 1H), 3.66 (t, J = 6.3 Hz,
2H), 2.85 (t, J = 6.0 Hz, 2H), 2.71 (t, J = 5.8 Hz, 2H), 2.61 (t, J = 7.2 Hz, 2H), 1.86 – 1.68 (m, 8H). 13C NMR
(d6-DMSO) δ 163.1, 158.5, 157.0, 131.2, 130.5, 120.4, 45.0, 32.9, 31.3, 25.2, 24.4, 24.1, 22.5, 21.8.
2-(2-Morpholinoethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (37a). General
Procedure D. Residue chromatographed on silica (1:99 Et3N:EtOAc) to yield the compound as a white solid
(800 mg, 56%). LCMS (m/z): 320.1 [M + H]+. HPLC: tR 4.909 min. HRMS (m/z): C16H21N3O2S requires
320.1433 [M + H]+; found 320.1427. 1H NMR (CDCl3) δ 12.51 (s, 1H), 3.82 – 3.71 (m, 4H), 2.96 (t, J = 5.9
Hz, 2H), 2.89 – 2.83 (m, 2H), 2.84 – 2.78 (m, 2H), 2.74 (t, J = 5.9 Hz, 2H), 2.62 – 2.56 (q, J = 3.8 Hz, 4H),
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1.90 – 1.73 (m, 4H). 13C NMR (CDCl3) δ 163.9, 159.7, 155.6, 132.6, 131.3, 121.4, 66.9, 55.7, 53.2, 30.1, 25.6, 
25.2, 23.1, 22.4.
2-(3-Morpholinopropyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one37 (37b).
General Procedure C. The reaction mixture was filtered directly and the solids washed with petroleum ether
to obtain the desired compound as a fluffy beige solid (3.51 g, 80%). LCMS (m/z): 334.1 [M + H]+. HPLC: tR
4.925 min. HRMS (m/z): C17H23N3O2S requires 334.1586 [M + H]+; found 334.1584. 1H NMR (d6-DMSO) δ 
11.54 (s, 1H), 3.99 – 3.81 (m, 4H), 3.42 (d, J = 12.3 Hz, 2H), 3.15 – 3.07 (m, 2H), 3.06 – 3.01 (m, 2H), 2.85
(t, J = 5.5 Hz, 2H), 2.70 (t, J = 7.2 Hz, 4H), 2.17 (dq, J = 15.4, 7.6 Hz, 2H), 1.86 – 1.69 (m, 4H). 13C NMR
(d6-DMSO) δ 162.9, 158.9, 156.5, 131.7, 131.0, 121.1, 63.5, 55.5, 51.3, 31.2, 25.7, 24.9, 22.9, 22.2, 20.8.
2-(4-Morpholinobutyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (37c). General
Procedure C. The reaction mixture was filtered directly and the solids collected and washed with hot i-PrOH
to afford the desired compound as a white solid (2.34 g, 57%). LCMS (m/z): 348.2 [M + H]+. HPLC: tR 5.034
min. HRMS (m/z): C18H25N3O2S requires 348.1749 [M + H]+; found 348.1740. 1H NMR (d6-DMSO) δ 11.36 
(s, 1H), 3.99 – 3.77 (m, 4H), 3.36 (d, J = 12.2 Hz, 2H), 3.13 – 2.93 (m, 2H), 2.83 (t, J = 5.6 Hz, 2H), 2.70 (t,
J = 5.5 Hz, 2H), 2.64 (t, J = 6.8 Hz, 2H), 1.86 – 1.63 (m, 8H). 13C NMR (d6-DMSO) δ 162.6, 158.5, 157.1, 
131.3, 130.7, 120.6, 63.2, 55.5, 50.9, 33.1, 25.4, 24.5, 24.0, 22.6, 22.1, 21.9.
4-(2-(4-Chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)ethyl)morpholine (38a).
General Procedure E. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the compound
as a gold oil (270 mg, 78%). LCMS (m/z): 338.1 [M + H]+. HPLC: tR 5.824 min. 1H NMR (CDCl3) δ 3.87 – 
3.52 (m, 4H), 3.29 – 3.12 (m, 2H), 3.05 (s, 2H), 2.98 – 2.89 (m, 2H), 2.85 (s, 2H), 2.59 – 2.50 (m, 4H), 1.94
– 1.84 (m, 4H). 13C NMR (CDCl3) δ 169.4, 163.3, 152.9, 138.1, 126.9, 126.4, 67.0, 57.2, 53.4, 35.9, 26.3, 
25.9, 22.5, 22.3.
4-(3-(4-Chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)propyl)morpholine (38b).
General Procedure E. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the compound
as a gold oil (1.06 g, 67%). LCMS (m/z): 352.1 [M + H]+. HPLC: tR 5.938 min. 1H NMR (CDCl3) δ 3.66 – 
3.61 (m, 4H), 3.08 – 2.95 (m, 4H), 2.88 – 2.78 (m, 2H), 2.47 – 2.37 (m, 4H), 2.11 – 2.00 (m, 2H), 1.91 (dt, J
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= 6.0, 2.9 Hz, 4H). 13C NMR (CDCl3) δ 169.4, 164.8, 152.8, 137.9, 126.9, 126.2, 66.9, 58.4, 53.6, 26.3, 25.9, 
25.4, 22.5, 22.2.
4-(4-(4-Chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)butyl)morpholine (38c).
General Procedure E. The residue was chromatographed on silica (1:99 Et3N:EtOAc) to afford the compound
as a gold oil (1.42 g, 88%). LCMS (m/z): 366.1 [M + H]+. HPLC: tR 6.255 min. 1H NMR (CDCl3) δ 3.75 – 
3.63 (m, 4H), 3.07 – 3.02 (m, 2H), 3.02 – 2.97 (m, 2H), 2.87 – 2.82 (m, 2H), 2.44 – 2.34 (m, 6H), 1.98 – 1.79
(m, 6H), 1.62 – 1.53 (m, 2H). 13C NMR (CDCl3) δ 169.4, 164.9, 152.9, 138.0, 126.9, 126.2, 66.9, 58.7, 53.7, 
26.5, 26.2, 26.2, 25.9, 22.5, 22.2.
2-(2-Morpholinoethyl)-N-(3-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-4-amine (39a). General Procedure F. The crude reaction mixture was concentrated under
reduced pressure and the residue chromatographed on silica (1:99 Et3N:EtOAc). The product was isolated and
found to have co-eluted with a reaction by-product (m/z: 347.2 [M + H]+), this mixture was concentrated under
reduced pressure, and the resulting bright yellow solid was suspended in Et2O. The solids were collected under
vacuum filtration & washed with Et2O to afford the desired compound as pale yellow crystalline solid (233
mg, 27%). LCMS (m/z): 463.2 [M + H]+. HPLC: tR 7.025 min. HRMS (m/z): C23H25F3N4O requires 463.1783
[M + H]+; found 463.1774. 1H NMR (CDCl3) δ 8.28 (s, 1H), 7.71 (dd, J = 7.9, 1.5 Hz, 1H), 7.44 (t, J = 7.9
Hz, 1H), 7.35 – 7.31 (m, 1H), 7.23 (s, 1H), 3.87 – 3.60 (m, 2H), 3.12 – 3.04 (m, 4H), 2.97 – 2.91 (m, 2H),
2.84 (t, J = 6.0 Hz, 2H), 2.59 – 2.49 (m, 4H), 2.07 – 1.89 (m, 4H). 13C NMR (CDCl3) δ 167.4, 163.3, 154.4, 
139.6, 134.4, 131.4 (q, J = 32.3 Hz), 129.4, 124.4, 124.1 (q, J = 272.4 Hz), 123.2, 119.8 (q, J = 3.8 Hz), 117.4
(q, J = 4.0 Hz), 114.7, 67.2, 57.4, 53.6, 36.3, 26.6, 25.6, 22.6, 22.5.
2-(3-Morpholinopropyl)-N-(3-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-4-amine (39b). General Procedure F. The residue was chromatographed on silica (1:99
Et3N:EtOAc) to afford the title compound as a light brown oil which later solidified under high vacuum to
give a dark white solid (383 mg, 56%). LCMS (m/z): 477.2 [M + H]+. HPLC: tR 6.671 min. HRMS (m/z):
C24H27F3N4OS requires 477.1937 [M + H]+; found 477.1930. 1H NMR (CDCl3) δ 8.24 (s, 1H), 7.78 (dd, J =
8.2, 1.8 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 7.36 – 7.31 (m, 1H), 7.22 (s, 1H), 3.70 – 3.66 (m, 4H), 3.07 (t, J =
6.0 Hz, 2H), 2.96 – 2.88 (m, 2H), 2.84 (t, J = 6.0 Hz, 2H), 2.44 (dd, J = 8.4, 6.6 Hz, 6H), 2.13 – 1.89 (m, 6H).
Page 67 of 82
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
68
13C NMR (CDCl3) δ 167.3, 164.7, 154.3, 139.5, 134.1, 131.3, (q, J = 32.1 Hz), 129.3, 124.3, 124.1, (q, J =
272.4 Hz), 123.1, 119.7, (q, J = 3.9 Hz), 117.2, (q, J = 4.0 Hz), 114.5, 67.1, 58.5, 53.6, 37.1, 26.5, 25.5, 25.2,
22.5, 22.4.
2-(4-Morpholinobutyl)-N-(3-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidin-4-amine (39c). General Procedure F. The residue was chromatographed on silica (1:99
Et3N:EtOAc) to afford the title compound as a pale yellow crystalline solid (400 mg, 59%). LCMS (m/z):
491.2 [M + H]+. HPLC: tR 6.671 min. HRMS (m/z): C25H29F3N4OS requires 491.2102 [M + H]+; found
491.2087. 1H NMR (CDCl3) δ 8.30 (s, 1H), 7.74 (dd, J = 8.2, 1.8 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 7.35 –
7.31 (m, 1H), 7.22 (s, 1H), 3.76 – 3.62 (m, 4H), 3.06 (t, J = 6.0 Hz, 2H), 2.94 – 2.88 (m, 2H), 2.84 (t, J = 6.0
Hz, 2H), 2.47 – 2.33 (m, 6H), 1.97 (dddd, J = 23.5, 21.1, 13.6, 8.1 Hz, 6H), 1.59 (tt, J = 9.8, 6.6 Hz, 2H). 13C
NMR (CDCl3) δ 167.3, 164.8, 154.2, 139.5, 134.1, 131.26, (q, J = 32.2 Hz), 129.3, 124.07, (q, J = 272.6 Hz),
123.0, 119.6, (q, J = 3.8 Hz), 117.19, (q, J = 4.0 Hz), 114.4, 67.0, 58.9, 53.7, 38.9, 26.5, 26.2, 25.5, 22.5, 22.4.
N,N-Diethyl-2-(4-morpholinobutyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (40).
General procedure F. Pale yellow solid (145 mg, 94%). mp: 60-62 °C. LCMS (m/z): 403.3 [M + H]+. HPLC:
tR 5.370 min. HRMS (m/z): C22H34N4OS requires 403.2532 [M + H]+; found 405.2326. 1H NMR (CDCl3) δ 
3.76 – 3.65 (m, 4H) 3.44 (q, J = 7.0 Hz, 4H) 2.94 – 2.79 (m, 6H) 2.45 (d, J = 3.8 Hz, 4H), 2.39 (dd, J = 8.6,
7.0 Hz, 2H), 1.96 – 1.88 (m, 2H), 1.87 – 1.81 (m, 2H), 1.78 (dtd, J = 8.9, 5.9, 2.9 Hz, 2H), 1.63 – 1.52 (m,
2H), 1.12 (t, J = 7.0 Hz, 6H). 13C NMR (CDCl3) δ 168.9, 163.5, 162.1, 132.8, 127.6, 119.6, 66.9, 58.9, 53.7, 
44.8, 38.8, 26.8, 26.5, 26.1, 25.9, 23.2, 23.1, 12.6.
2-(4-Morpholinobutyl)thieno[2,3-d]pyrimidin-4(3H)-one (41). General Procedure C. The reaction vessel
was decanted leaving a dark solid mass. The vessel was washed with 1,4-dioxane and the solids were collected
and stirred in hot 1,4-dioxane to wash away any 1,4-dioxane soluble impurities. The crude solid was
chromatographed on silica (5% MeOH-DCM) affording the desired compound as a fluffy beige solid (1.22 g,
57%). LCMS (m/z): 294.2 [M + H]+. HPLC: tR 3.664 min. HRMS (m/z): C14H19N3O2S requires 294.1277 [M
+ H]+; found 294.1271. 1H NMR (CDCl3) δ 7.44 (d, J = 5.8 Hz, 1H), 7.19 (d, J = 5.8 Hz, 1H), 3.78 – 3.73 (m,
4H), 2.87 (t, J = 7.5 Hz, 2H), 2.51 – 2.48 (m, 2H), 2.47 – 2.43 (m, 2H), 1.90 (dt, J = 15.1, 7.5 Hz, 2H), 1.70 –
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1.61 (m, 2H). 13C NMR (CDCl3) δ 166.0, 160.1, 157.8, 122.3, 122.2, 121.4, 66.4, 58.1, 53.4, 45.8, 34.4, 25.3, 
25.2.
4-(4-(4-Chlorothieno[2,3-d]pyrimidin-2-yl)butyl)morpholine (42). General Procedure D. The residue was
chromatographed on silica (1:99 Et3N-EtOAc) which afforded the desired compound as a golden oil (485 mg,
51%). LCMS (m/z): 312.2 [M + H]+. HPLC: tR 4.734 min. 1H NMR (CDCl3) δ 7.52 (d, J = 6.0 Hz, 1H), 7.39
(d, J = 6.0 Hz, 1H), 3.73 – 3.69 (m, 4H), 3.10 – 3.02 (m, 2H), 2.46 – 2.42 (m, 4H), 2.42 – 2.37 (m, 2H), 1.92
(dt, J = 15.5, 7.7 Hz, 2H), 1.60 (ddd, J = 17.9, 8.6, 6.7 Hz, 2H). 13C NMR (CDCl3) δ 169.6, 166.5, 154.9, 
127.2, 127.1, 119.9, 67.1, 58.9, 53.9, 38.9, 26.7, 26.3.
2-(4-Morpholinobutyl)-N-(3-(trifluoromethyl)phenyl)thieno[2,3-d]pyrimidin-4-amine (43a). General
procedure F. The solvent was concentrated in vacuo and the brown residue was chromatographed on silica
(98:1:1 EtOAc/MeOH/Et3N) furnishing the target compound as a transparent oil, later turning into a white
powder under high vacuum (201 mg, 80%). LCMS (m/z): 437.2 [M + H]+. HPLC: tR 5.670 min. HRMS (m/z):
C21H23F3N4OS: requires 437.1621 [M + H]+; found 437.1617. 1H NMR (CDCl3) δ 8.33 (t, J = 1.8 Hz, 1H),
7.80 (dd, J = 8.1, 0.8 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.40 (s, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 6.0
Hz, 1H), 7.25 (d, J = 6.0 Hz, 1H), 3.73 – 3.67 (m, 4H), 3.00 – 2.94 (m, 2H), 2.46 – 2.34 (m, J = 13.7, 6.1 Hz,
6H), 1.98 – 1.88 (m, 2H), 1.64 – 1.55 (m, 2H). 13C NMR (CDCl3) δ 168.4, 166.2, 154.4, 139.5, 131.31 (q, J
= 32.3 Hz), 129.4, 123.9 (q, J = 272.2 Hz), 123.4, 123.3, 120.0 (q, J = 3.7 Hz), 117.6 (q, J = 4.0 Hz), 116.6,
114.8, 67.0, 58.8, 53.7, 39.1, 26.2.
N,N-Diethyl-2-(4-morpholinobutyl)thieno[2,3-d]pyrimidin-4-amine (43b). General procedure F. The
solvents were evaporated under reduced pressure and the residue was chromatographed on silica (3:2
EtOAc:petroleum ether) furnishing the desired compound as a gold oil (178 mg, 89%). LCMS (m/z): 349.2
[M + H]+. HPLC: tR 4.108 min. HRMS (m/z): C18H28N4OS: requires 349.2063 [M + H]+; found 349.2057. 1H
NMR (CDCl3) δ 7.26 (d, J = 6.2 Hz, 1H), 7.09 (d, J = 6.2 Hz, 1H), 3.74 (q, J = 7.1 Hz, 4H), 3.70 (dd, J = 7.8,
3.1 Hz, 4H), 2.81 (t, J = 7.5 Hz, 2H), 2.44 – 2.41 (m, 4H), 2.40 – 2.35 (m, 2H), 1.86 (dt, J = 15.3, 7.6 Hz, 2H),
1.58 (tt, J = 9.8, 6.6 Hz, 2H), 1.31 (t, J = 7.0 Hz, 6H). 13C NMR (CDCl3) δ 169.9, 165.2, 156.9, 121.2, 119.3, 
112.5, 67.1, 59.1, 53.8, 43.9, 38.9, 26.7, 26.3, 13.4.
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N,N-diethyl-2-(morpholinomethyl)thieno[2,3-d]pyrimidin-4-amine (44). General procedure F. The
solution was concentrated under reduced pressure and the residue chromatographed on silica (4:1 EtOAc:
petroleum ether) affording the desired compound as a light brown oil (125 mg, 94%). mp: 60-62 °C. LCMS
(m/z): 262.1 [M + H]+. HPLC: tR 6.281 min. HRMS (m/z): C15H22N4OS requires 307.1589 [M + H]+; found
307.1587. 1H NMR (CDCl3) δ 7.29 (d, J = 6.2 Hz, 1H), 7.15 (d, J = 6.2 Hz, 1H), 3.80 – 3.77 (m, 4H), 3.76
(dd, J = 12.4, 5.5 Hz, 4H), 3.71 (s, 2H), 2.75 – 2.59 (m, 4H), 1.31 (t, J = 7.0 Hz, 3H). 13C NMR (CDCl3) δ 
169.9, 160.9, 156.8, 121.1, 120.2, 113.1, 66.9, 65.2, 53.8, 44.0, 13.4.
Thieno[2,3-d]pyrimidin-4(3H)-one (45). Ethyl 2-aminothiophene-3-carboxylate (1.25 g, 7.30 mmol) was
taken up in formamide (15 mL) and heated to 170 °C under a N2 atmosphere. The heating was continued for
5 h, in which the progress of the reaction was monitored by LC/MS. The crude reaction mixture was diluted
with EtOAc and extracted with aqueous 1M HCl solution (3 x 30 mL). The organic extracts were discarded,
the aqueous phase adjusted to ~pH 10 and further extracted with EtOAc (3 x 30 mL). The organic extracts
were collected and dried over anhydrous sodium sulphate and the solvent was concentrated under reduced
pressure affording the compound as a yellow solid (845 mg, 76%). LCMS (m/z): 153.1 [M + H]+. HPLC: tR
3.424 min. 1H NMR (d6-DMSO) δ 12.50 (s, 1H), 8.14 (s, 1H, ), 7.59 (d, J = 5.8 Hz, 1H), 7.41 (d, J = 5.8 Hz,
1H). 13C NMR (d6-DMSO) δ 164.6, 157.9, 146.1, 125.1, 124.3, 122.1. 
4-Chlorothieno[2,3-d]pyrimidine (46). General Procedure E. The black crude residue was chromatographed
on silica (60:40 EtOAc:petroleum ether) to afford the compound as a fluffy beige solid (695 mg, 77%). LCMS
(m/z): 170.9 [M + H]+. HPLC: tR 5.394 min. 1H NMR (CDCl3) δ 8.88 (s, 1H), 7.64 (d, J = 6.0 Hz, 1H), 7.46
(d, J = 6.0 Hz, 1H). 13C NMR (CDCl3) δ 168.8, 155.0, 152.8, 129.6, 128.4, 119.2.
N-(3-(trifluoromethyl)phenyl)thieno[2,3-d]pyrimidin-4-amine (47a). General procedure F. The solvent
was evaporated under reduced pressure and the residue was chromatographed on silica (70:29:1 petroleum
ether:EtOAc:Et3N). This afforded the target compound as a white/pale yellow solid (225 mg, 65%). mp: 60-
62 °C. LCMS (m/z): 296.0 [M + H]+. HPLC: tR 6.842 min. HRMS (m/z): C13H8F3N3S requires 296.0466 [M
+ H]+; found 296.0464. 1H NMR (400 MHz, d6-DMSO) δ 9.92 (s, 1H), 8.60 (s, 1H), 8.33 (t, J = 2.0 Hz, 1H),
8.23 (dd, J = 8.1, 2.0 Hz, 1H), 7.93 (d, J = 6.0 Hz, 1H), 7.80 (d, J = 6.0 Hz, 1H), 7.63 (t, J = 8.0 Hz, 1H), 7.44
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(ddt, J = 7.8, 1.7, 0.9 Hz, 1H). 13C NMR (d6-DMSO) δ 166.8, 154.5, 152.9, 140.3, 129.7, 129.3 (d, J = 31.5
Hz), 124.5, 124.3 (q, J = 272.6 Hz), 119.4, 119.2 (q, J = 3.7 Hz), 117.2, 116.9 (q, J = 4.0 Hz).
N,N-diethylthieno[2,3-d]pyrimidin-4-amine (47b). General procedure F. The bright blue crude reaction was
evaporated of any volatile solvents and the resulting residue chromatographed on silica (50:50 petroleum
ether:EtOAc) affording the compound as a light green powder (223 mg, 91%). LCMS (m/z): 208.1 [M + H]+.
HPLC: tR 4.098 min. HRMS (m/z): C10H13N3S: requires 208.0984 [M + H]+; found 208.0903. 1H NMR
(CDCl3) δ 8.43 (s, 1H), 7.32 (d, J = 6.2 Hz, 1H), 7.19 (d, J = 6.2 Hz, 1H), 3.76 (q, J = 7.1 Hz, 4H), 1.33 (t, J
= 7.1 Hz, 6H). 13C NMR (CDCl3) δ 169.1, 157.1, 153.1, 121.4, 120.5, 114.8, 44.1, 13.3.
Pharmacological Characterisation. Materials. Dulbecco’s modified Eagle’s medium, Flp-In CHO cells, and
hygromycin B were purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was purchased
from ThermoTrace (Melbourne, VIC, Australia). [3H]raclopride, GF/C 96-well filter plates, and MicroScint-
0 were from PerkinElmer (Boston, MA). All other reagents were purchased from Sigma Aldrich (St. Louis,
MO).
Cell culture. FlpIn Chinese Hamster Ovary (CHO) cells (Invitrogen, Carlsbad, CA, USA) stably
expressing the hD2LR were grown and maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), and 200 μg/mL of Hygromycin-B, and maintained at 37
°C in a humidified incubator containing 5% CO2.
[3H]Raclopride Binding Assay: The membranes of FlpIn CHO cells expressing the hD2LR were
prepared as previously described.38 Radioligand inhibition assays were performed by co-incubating membrane
homogenates (15 μg protein) with varying concentrations of test compound in binding buffer (20 mM HEPES,
100 mM NaCl, 6 mM MgCl2, 1 mM EGTA, 1 mM EDTA; pH 7.4) containing 0.5 nM of [3H]raclopride to a
final volume of 300 µL in the absence or presence of the competing compounds, and incubated at 25 °C for
2-3 h. Each test compound was dissolved in dimethyl sulfoxide and diluted in the binding buffer into 10 half-
10log serial dilutions: final test concentrations ranged from 10-3 M to 10-7 M. All compound concentrations
were tested in duplicate. Nonspecific binding was determined using 10 μM haloperidol (Sigma-Aldrich, St.
Louis, MO. In the kinetic binding assay, the dissociation of [3H]raclopride was started after being incubated
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for 60 minutes. Binding was terminated by fast flow filtration over GF/C membrane unifilter plates
(PerkinElmer) using a Uniplate 96-well harvester (PerkinElmer) followed by five washes with ice-cold 0.9%
NaCl. MicroScint-0 (50 μL/well) was added, plates were sealed (TopSeal™), and radioactivity was measured
in a MicroBeta2 LumiJET MicroBeta counter (PerkinElmer). The affinity (Kd) of [3H]raclopride at the D2LR
determined in saturation binding assays is 1.07 ± 0.12 nM and the Bmax value is 1.51 ± 0.26 pmol/mg protein.
Cell culture and transfection for cAMP assay: FlpIn CHO cells stably expressing the human dopamine
D2L receptor were maintained in DMEM supplemented with 5% foetal calf serum (FBS) and 0.2 mg/mL
hygromycin at 37 °C in a humidified incubator supplied with 5% CO2. For transfection, the cells were grown
in 10 cm culture dishes until sub-confluent. A mixture of 4 μg plasmid DNA containing BRET-based cAMP
(CAMYEL) biosensor construct29 and 25 μg 20 kDa linear polyethylene imine (PEI) in 500 μL 150 mM NaCl
was added into a dish of cells.
cAMP measurement: The cellular cAMP levels were measured with the CAMYEL BRET-based
biosensor for cAMP.29 One day after transfection, cells were trypsinised and seeded in white 96-well
microplates. The cells were then cultured for an additional day, rinsed twice with Hank's Balanced Salt
Solution (HBSS) and were then incubated in fresh HBSS. The Renilla luciferase (RLuc) substrate
coelenterazine-h was added to reach a final concentration of 5 µM. The cells were stimulated with dopamine
in the presence of 10 μM forskolin (final concentration). For the antagonism assay, the antagonists were added
30 min prior to stimulation. The BRET signals were measured using a BMG Lumistar counter 30 min after
stimulation. The BRET signal (BRET ratio) was determined by calculating the ratio of the light emitted at 535
± 30 nm (YFP) to the light emitted at 475 ± 30 nm (RLuc).
Data analysis. Computerized nonlinear regression, statistical analyses and simulations were performed
using Prism 6.0 (GraphPad Prism 6.0b Software, San Diego, CA).
Analysis of radioligand binding experiments:
Competition-binding curves between [3H]raclopride and 1 and analogues of 1 were fitted to the allosteric
ternary complex model using the following equation.27
(1)
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where Y is percentage (vehicle control) binding; [A] and [B] are the concentrations of [3H]raclopride and
modulator, respectively; KA and KB are the equilibrium dissociation constants of [3H]raclopride and modulator,
respectively; and α is the cooperativity between [3H]raclopride and modulator. Values of α >1 denote positive 
cooperativity, values <1 (but > 0) denote negative cooperativity and values = 1 denote neutral cooperativity.
For analogues of 1 that displayed incomplete displacement of [3H]raclopride, a value of α could be determined 
experimentally. However, for analogues that acted to completely displace the radioligand then we could not
distinguish an allosteric mode of action (with high negative cooperativity) from a competitive mode of
interaction. In these cases, we fit the above model fixing the value of α to assume high negative cooperativity
(α = 0.0001). Values of KB determined using this fit did not deviate significantly from values of affinity derived
using a competitive model.
Radioligand binding dissociation kinetic data was analysed and fit to an exponential decay equation using
non-linear regression to determine the rate constant.
Total Binding = NS + (Total − NS) ×               (2)
Where NS is non-specific binding and t is time expressed in minutes. The dissociation rate constant (koff) is
expressed in units of inverse, min-1-. The half-life for dissociation is also calculated as ln(2)/koff or 0.6931/koff.
Analysis of functional data. All concentration-response data were fitted to the following modified four-
parameter Hill equation to derive potency estimates.39
  =           + (                    ).[   ]    [       ]              (3)
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where E is the effect of the system, nH is the Hill slope and EC50 is the concentration of agonist [A] that gives
the midpoint response between basal and maximal effect of dopamine or other agonists (Emax), which are the
lower and upper asymptotes of the response, respectively.
To determine the mode of interaction of 1 and derivaites of 1 at the D2R in relation to the agonist dopamine,
data were fit to both a competitive and allosteric model and the best fit compared statistically. A logistic
equation of competitive agonist-antagonist interaction was globally fitted to data from functional experiments
measuring the interaction between dopamine and all analogues of 1:
                =             + (                      )
   
⎝
⎛    
                   
[   ]
         
   
 
[  ]
⎠
⎞
    (4)
Where s represents the Schild slope for the antagonist and pA2 represents the negative logarithm of the molar
concentration of antagonist that makes it necessary to double the concentration of agonist needed to elicit the
original submaximal response obtained in the absence of antagonist. The same data describing the interaction
between all analogues of 1 and dopamine were also analyzed using a complete operational model of
allosterism and agonism according to equation 5:27
  =     (    [   ](    	       [   ])      [   ]   	  )   ([   ]                     [   ]     [   ][   ])      (    [   ](           [   ])      [   ]     )    (5)
Where Em is the maximum possible cellular response, [A] and [B] are the concentrations of orthosteric and
allosteric ligands, respectively, KA and KB are the equilibrium dissociation constant of the orthosteric and
allosteric ligands, respectively, τA and τB (constrained to -100) are operational measures of orthosteric and
allosteric ligand efficacy (which incorporate both signal efficiency and receptor density), respectively, α is the
binding cooperativity parameter between the orthosteric and allosteric ligand, and β denotes the magnitude of
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the allosteric effect of the modulator on the efficacy of the orthosteric agonist. KA was constrained to 617 nM,
and represents a value of functional affinity determined by an operational model of agonism applied to dose-
response data of dopamine in the presence of increasing concentrations of the alkylating agent
phenoxybenzamine. For compounds that caused a limited rightward shift of the dopamine dose-response curve
but no decrease in Emax, data were fit using an operational model of allosterism where Logβ was constrained
to 0 to represent neutral cooperativity with dopamine efficacy. For compounds that produced an unlimited
decrease in the maximal response of dopamine Logβ was constrained to -100.
For each of the compounds the two equations (models) were then compared for their fit using an extra-
sum-of-squares F test. All of the data points and values shown in the figures and tables are the mean ± s.e.m.
of at least three separate experiments performed in duplicate unless otherwise stated.
Molecular Docking Simulations. The D2R crystal structure (PDB ID 6C38)32 was prepared by the
regularisation algorithm implemented in ICM-Pro molecular modeling software.40 Raclopride was docked
into the orthosteric pocket of the D2R using an energy-based docking protocol implemented in the ICM-Pro
software.40 The best energy binding pose predicted for raclopride in the D2R was found to be similar to the
binding pose of closely related eticlopride in the co-crystallised complex with the D3R.42 The D2R-raclopride
complex was further optimised using Biased Probability Monte Carlo (BPMC) optimisation of the surrounding
residues in the proximity of 5 Å of ligand. In the final D2R-raclopride complex, the RMSD between common
atoms of raclopride and the crystallographic pose of eticlopride did not exceed 0.5 Å.
Compound 1 and its thirty-three analogues were docked into the D2R-raclopride complex using an energy-
based docking protocol implemented in the ICM-Pro software.40, 41 Compounds were generated from 2D
representations and their 3D geometry was optimised using MMFF-94 force field. The docking was performed
in the rectangular box that comprised the whole extracellular part of the receptor above raclopride, including
the extracellular loops. Docking simulations used BPMC optimisation of the compounds internal coordinates
in the pre-calculated grid energy potentials of the receptor. The exhaustive sampling of the compound
conformational space was done with the thoroughness parameter set to 10, and at least three independent
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docking runs performed for each compound. The final docking poses were selected based on optimal ligand
receptor interactions and ICM binding scores.
For D3R docking, we used the previously published D3R-eticlopride crystal structure (PDB ID: 3PBL)9, where
raclopride was docked in place of eticlopride. Compound 1 and its eight analogues were then docked into
D3R-raclopride complex. Due to the hypothesised high flexibility of the E902.65 residue side chain, it was set
up as “explicitly flexible group” during the docking. Further docking method was used as abovementioned.
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 ABBREVIATION LIST
cAMP, cyclic adenosine monophosphate; D2R, dopamine D2 receptor; D3R, dopamine D3 receptor; dopamine,
DA; GPCR, G protein-coupled receptor; FGA, first-generation antipsychotic; SGA, second-generation
antipsychotic; EPS, extrapyramidal symptoms; NAM, negative allosteric modulator; VLS, virtual ligand
screening; SAR, structure-activity relationship; CHO, chinese hampster ovary; cAMP, cyclic adenosine
monophosphate; BRET, bioluminescence resonance energy transfer; FBS, foetal bovine serum; HBSS, hank's
balanced salt solution; SEM, standard error of mean; DMF, N,N-dimethylformamide, POCl3, phosphorus
oxychloride; i-PrOH, isopropyl alcohol; EtOAc, ethyl acetate; DCM, dichloromethane; MWI, microwave
irradiation; TRIDENT, tris[2-(2-methoxyethoxy)ethyl]amine.
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